

CURRICULUM VITAE

ARMANDO SARDI, M.D., FACS

PRESENT POSITION Chief Surgical Oncology
Medical Director, Institute for Cancer Care
Mercy Medical Center, Baltimore, Maryland

BUSINESS ADDRESS Institute for Cancer Care at Mercy
Division of Surgical Oncology
4th Floor Weinberg Building
227 Saint Paul Place
Baltimore, Maryland 21202
(410)-332-9294-OFFICE
(410)-332-9731-FAX

LANGUAGE Fluent in English
Primary Language Spoken: Spanish

DEGREES M.D. Universidad del Valle
Cali, Colombia - S.A.
1973-1980

POST GRADUATE TRAINING Hospital Santander
San Andres Island, Colombia - S.A.
1980-1981 Rural Service*

* Required by the Colombian Ministry of Education and Health for all medical graduates of Colombia.

INTERNSHIP Universidad del Valle
Cali, Colombia - S.A.
1979-1980 Rotating Internship

South Baltimore General Hospital
Baltimore, Maryland - U.S.A.
1981-1982 Surgical Intern

RESIDENCY South Baltimore General Hospital
Baltimore, Maryland - U.S.A.
1982-1983 Surgical Resident

Saint Agnes Hospital
Baltimore, Maryland - U.S.A.
1983-1985 Surgical Resident

RESIDENCY Saint Agnes Hospital
Baltimore, Maryland - U.S.A.
1985-1986 Surgical Oncology Fellow & Surgical Chief Resident

FELLOWSHIP Ohio State University Hospital
Division of Surgical Oncology

Columbus, Ohio - U.S.A.
1986-1988

American Cancer Society
Clinical Fellowship Grant
1987-1988

CERTIFICATIONS

American Board of Surgery

NIH certified on the Protection of Human Research Subjects (12/2000)

HONORS AND AWARDS

Full scholarship for occupying first place (1/95) in medical school. March 1974 through February 1975.

Full scholarship for attaining/receiving first place (1/92) in medical school. April 1975 through March 1976.

Cianos Award - Saint Agnes Hospital. June 1984, (awarded to the surgical resident who has demonstrated more extensive knowledge in basic sciences).

Cianos Award - Saint Agnes Hospital. June 1986, (awarded to the surgical resident who has demonstrated more extensive knowledge in basic sciences).

First place winner, Ohio Chapter American College of Surgeons Resident Essay Contest, "Localization of tumor labeled with antibody 'cocktail' by hand-held gamma probe", 1988.

Second place winner, Ohio Chapter of the American College of Surgeons Resident Essay Contest, "The use of a hand-held gamma detector improves the safety of isolated limb perfusion", 1988.

"The Spirit of Caring" Award, Ochsner Clinic, New Orleans, LA, 1991-1993

Teacher of the Year and Outstanding Attending in General Surgery, 1996-97 by the Surgical House staff at St. Agnes Hospital.

"Hands Humanitarian Award", by the Hands Across America Organization in recognition of his voluntary treatment for children in need throughout America, Baltimore, Maryland. November 30, 2001.

Governor's Citation of the State of Maryland for the successful mission in Hands Across America, Inc. November 30, 2001

Founder's Award for the year 2003. This physician of the year award is given to the physician that has demonstrated performance as an exemplary physician during his years of service at St. Agnes HealthCare.

The Daily Record, Healthcare Heroes Award for "Advancements in Healthcare." Baltimore, Maryland March 28, 2007

“Premio Colombia Exterior A La Excelencia 2007.” This award was presented for excellence in science. Broadway, NY May 11, 2007

“Hispanic Hero” at the 3rd Annual Maryland Hispanic Youth Symposium. Baltimore, Maryland July 19, 2007

“Gold Star Caregiver Award.” Presented by The Sisters of Mercy in recognition of Gold Star Care performance and patient compliments. September 4, 2007

“Visitante Ilustre De Santiago De Cali.” Presented by the Mayor of City of Cali Colombia. February 26, 2008

Gobernador Citation Valle Del Cauca – Colombia for the contribution to improve the quality of life of the poorest and more vulnerable people. February 26, 2008

“La Medalla Santiago de Cali en el Grado Cruz de Oro.” Presented by Concejo Municipal of City of Cali Colombia February 29, 2008

“Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur.” Presented by USHYEE. Baltimore, MD June 5, 2008

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2009

“Gold Star Teamwork Award.” Presented by The Sisters of Mercy in recognition of Gold Star performance. December 2009

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2011

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2012

Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity and perseverance of Colombia. Bogota, Colombia December 2012

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2014

Recognized by Castle Connolly as a “Top Doctor” June 2016

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2016

Recognized by Castle Connolly as a “Top Doctor” June 2017

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2017

“Gold Star Caregiver Award.” Presented by The Sisters of Mercy, in recognition of Gold Star Care performance and patient compliments September 2018

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2019

Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2020

MEDICAL ASSOCIATIONS:

1. American College of Surgeons
2. Society of Surgical Oncology
3. American Society of Clinical Oncology
4. The Society for Surgery of the Alimentary Tract
5. Medical and Chirurgical Faculty of Maryland
6. Southeastern Surgical Association
7. American Medical Association
8. Association of the Alumni of the "Division de Salud of the Universidad del Valle
9. National Cancer Institute - Clinical Investigator
10. American Society of Peritoneal Surface Malignancies, Chairperson, Mid-Atlantic Chapter
11. PMP Research Foundation
12. Peritoneal Surface Oncology Group International

APPOINTMENTS:

- 1988-1993: Staff Surgical Oncology - General Surgery, Alton Ochsner Medical Foundation
- 1988-1993: Clinical Assistant Professor of Surgery, Tulane University Medical Center
- 1990-1993: Medical Director, Surgical Technology Program, Ochsner School of Allied Health Sciences
- 1991-1993: Louisiana District #1 Committee on Applicants of the American College of Surgeons
- 1993-1994: Founding Chief, Division of Surgical Oncology, Health Care International (Scotland) Ltd
- 1993-1994: Co-Director of Oncology Program, Health Care International (Scotland) Ltd.
- 1994-2006: Chief, Surgical Oncology, Saint Ages Health Care
- 1996-1997: Member, Editorial board of the Maryland Medical Journal (MMJ)
- 1997-1998: Member, Membership committee of the Society of Head and Neck Surgeons
- 1998-2006: Founding Medical Director, Clinical Research Center
- 2000-2003: Member, Editorial Board of Clinical Researcher
- 2003-present: Faculty and Preceptor, Ethicon Endosurgery Institute

2005-present: Member, Scientific Council of Colombia Médica- Universidad del Valle
2006-2011: Member, Scientific Review Committee, Mercy Medical Center
2006-present: Medical Director, Annual Colombia Medical Mission
2006-present: Director, The Institute for Cancer Care, Mercy Medical Center
2006-present: Chief, Surgical Oncology, Mercy Medical Center
2008-present: The Commission on Cancer's Cancer Liaison Physician
2009-present: Member, Editorial Board of Colombia Médica - Universidad del Valle
2011-present: Founder and President, Partners for Cancer Care and Prevention/Fundación Prevención y Tratamiento del Cáncer en Cali-Colombia
2012-present: CTEP Investigator
2018-present: Member, ACPMP Research Foundation Professional Advisory Board

HOSPITAL COMMITTEES:

Ochsner Medical Institutions:

1989-1993: Oncology
1992-1993: Operating Room
1992-1993: Pre-Operative Testing

Health Care International (Scotland),Ltd.

1993-1994: Oncology
1993-1994: Patient Education
1993-1994: Drug and Therapeutics
1993-1994: Clinical Systems Users

St. Agnes HealthCare

1994-2006: Cancer Committee
1994-1997: Patient Education
1994-2006: Institutional Review Board
1998-2006: Clinical Research Board of Directors

Mercy Medical Center

2006-present: Director, The Institute for Cancer Care
2006-present: Cancer Committee
2008-present: Cancer Liaison Physician

CURRENT PROJECTS:

1. **Sardi A** Microbiologic and immune characteristics of peritoneal tissues in patients with appendiceal cancer with peritoneal spread. MMC 2010-31, 2010 to present
2. **Sardi A.** A study of tissue molecular markers and their relationship to treatment and outcome in appendiceal cancer with pseudomyxoma peritonei (PMP). MMC 2010-33, 2010 to present
3. **Sardi A.** Surgical oncology research database and tissue resource study. MMC 2010-37, 2010-present.
4. **Sardi A.**, Diaz-Montes TM. A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by

adjuvant chemotherapy as initial treatment of advanced stage (stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer, NCT02124421, 2014 to present

5. **Sardi A.** Clinical trial to define the effect of perioperative *H. Pylori* eradication with antibiotic treatment on the long term outcomes of patients with pseudomyxoma peritonei of appendiceal origin undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). NCT02387203, 2014 to present
6. **Sardi A.**, Knight R. A cohort study of the gastrointestinal microbiome in appendiceal cancer with peritoneal spread. A case control, cohort study to determine whether the gut microbiome of participants with appendiceal tumors with peritoneal spread differs from a healthy, age-matched cohort. MMC 2015-53, 2105-present
7. **Sardi A.**, Diaz-Montes TP. Clinical outcome and feasibility of hyperthermic intraperitoneal chemotherapy in treatment of uterine leiomyosarcoma. MMC 2015-60, 2015-present
8. **Sardi A.**, Bijelic L. Identification of genomic alterations in diffuse malignant peritoneal mesothelioma. A retrospective observational cross-sectional study to characterize and describe the genomic profile of malignant peritoneal mesothelioma. MMC 2016-35, 2016-present
9. **Sardi A.**, Diaz-Montes TP. Next Generation Sequencing and analysis of mutations in ovarian, fallopian tube, and primary peritoneal cancers in a cohort of patients who underwent cytoreductive surgery and/or hyperthermic intraperitoneal chemotherapy. MMC 2017-44, 2017-present.
10. **Sardi A.**, Diaz-Montes TP. The use of hyperthermic intraoperative chemotherapy at the time of interval cytoreductive surgery in patients managed with neo-adjuvant chemotherapy for Mullerian cancers. MMC 2017-49, 2017-present.
11. **Sardi A.**, Identification of somatic genetic alterations in first degree relatives in appendiceal cancer. 2018-present.

PRESENTATIONS:

1. **Sardi A.**, Gokli A, Singer J. Diverticular disease of the cecum and ascending colon: A review of 881 cases. Poster presentation, Southeastern Surgical Congress, New Orleans, LA, March 16-19, 1986
2. **Sardi A.**, Parikh K, Singer J, Minken S. Mesenteric cysts. Poster presentation, Southeastern Surgical Congress, New Orleans, LA, March 16-19, 1986
3. **Sardi A.**, Gokli A, Singer J. Diverticular disease of the cecum and ascending colon: A review of 881 cases. Presented at surgical grand rounds, Saint Agnes Hospital, Baltimore, MD, June 11, 1986
4. **Sardi A.**, Rousseau M, Gersman M, Hinkle GH, Olsen J, Tuttle S, Houchens D, Thurston MO, Martin EW Jr. Localization of tumor labeled with antibody 'cocktail' by hand-held gamma probe. Poster presentation, American Society of Colon and Rectal Surgeons, Washington DC, April 1987
5. Sickie-Santanello BJ, O'Dwyer PJ, Mojzisek C, Tuttle SE, Hinkle GH, Rousseau M, Schlom J, Colcher D, Thurston MO, Nieroda C, **Sardi A.**, Farrar WB, Minton JP, Martin EW Jr.

Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Presented to the American Society of Colon and Rectal Surgeons Annual Meeting, Washington, DC, April 5-10, 1987

6. Siddiqi MA, Hinkle GH, Hill TL, Mojzisek CM, Olsen J, Rousseau M, Gersman M, Houchens D, **Sardi A**, Thurston MO, Martin EW Jr. An assessment of prolonged reactivity of seven monoclonal antibodies against in situ CX-1 tumor xenografts using a novel hand-held gamma detecting probe. Presented at the Third Annual Scientific Session of the Academy of Surgical Research, Washington, DC, September 10-12, 1987
7. Nieroda CA, Farrar WB, Mojzisek C, **Sardi A**, Siddiqi MA, Ferrara PJ, Tuttle S, James A, Martin EW. A phase I study of the intraoperative detection of residual and metastatic breast cancer. Presented at the 10th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-12, 1987
8. **Sardi A**, Siddiqi MA, Hinkle GH, Rousseau M, Gersman M, Hill T, Olsen J, Tuttle S, Young D, Houchens D, Thurston MO, Martin EW Jr. Localization of tumor labeled with antibody 'cocktail' by hand-held gamma probe. Presented at the 33rd Annual Meeting of the Ohio Chapter of American College of Surgeons, Resident Essay Contest, Akron, OH, May 5-7, 1988. First place winner Resident Essay contest and Extraordinary Oncology Award Winner.
9. **Sardi A**, Workman M, Mojzisek C, Hinkle GH, Nieroda CA, Ferrara PJ, Agnone C, Farrar WB, Martin EW Jr. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS). Presented at the 1988 Annual Meeting of the Society of Surgical Oncology, New Orleans, LA, May 22-25, 1988
10. **Sardi A**, Minton JP, Mojzisek C, Nieroda CA, Ferrara PJ, Thurston MO, Martin EW Jr. The use of a hand-held gamma detector improves the safety of isolated limb perfusion. Poster presentation, 1988 Annual Meeting of the Society of Surgical Oncology, New Orleans, LA, May 22-25, 1988
11. **Sardi A**, Workman M, Mojzisek C, Hinkle G, Nieroda C, Martin EW Jr. Intraabdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS) system. Presented in the 1988 Annual Meeting of the Society of Surgical Oncology, New Orleans, LA, May 24, 1988
12. Nieroda CA, Mojzisek C, **Sardi A**, Ferrara P, Hinkle G, Thurston MO, Martin EW Jr. The impact of radioimmunoguided surgery (RIGS) on surgical decision-making in colorectal cancer. Presented at the 1988 Annual Meeting of the American Society of Colon and Rectal Surgeons, Anaheim, CA, June 12-17, 1988
13. Ferrara P, Hinkle G, Nieroda C, **Sardi A**, Hill T, Thurston MO, Martin EW. A dual-labeled monoclonal antibody allows radioimmunodetection (RID) and radioimmunoguided surgery (RIGS). Presented at the 1988 Annual Meeting of the American Society of Colon and Rectal Surgeons, Anaheim, CA, June 12-17, 1988
14. **Sardi A**, Agnone C, Nieroda CA, Mojzisek C, Hinkle GH, Ferrara P, Farrar WB, Bolton JS, Thurston MO, Martin EW Jr. Radioimmunoguided surgery in recurrent colorectal cancer: The role of CEA, CAT scan, and physical examination. Presented in the Section of Colorectal Surgery at the 82nd Annual Scientific Assembly of the Southern Medical Association, New Orleans, LA, November 6-9, 1988
15. **Sardi A**, Radioimmunoguided surgery. Presented at the Association of Surgical Technologists of Louisiana Meeting, New Orleans, LA, February 1, 1989

16. **Sardi A.** Radioimmunoguided surgery. Presented at Ochsner Clinic Baton Rouge Satellite, Baton Rouge, LA, February 28, 1989
17. **Sardi A.** Surgical approach to recurrent colorectal cancer. Presented at North Central Cancer Treatment Group Meeting, Rochester, MN, April 5-7, 1989
18. Nieroda C, Mojzisek C, Ferrara P, **Sardi A**, Hinkle G, Thurston M, Martin EW Jr. Radioimmunoguided surgery in primary colon cancer. Presented at the 3rd International Symposium on Immunobiology in Clinical Oncology, Nice France, April 9-11, 1989
19. **Sardi A**, Agnone C, Anderson G, Bolton JS, Sundgaard-Riise K, Nieroda C, Minton JP. Low dose cyclophosphamide enhances helper-to-non-helper ratios. Presented at the 3rd International Symposium on Immunobiology in Clinical Oncology, Nice France, April 9-11, 1989
20. **Sardi A**, Martin EW Jr. The use of radioimmunoguided surgery in resecting retroperitoneal recurrent colorectal cancer. Presented in video form at the 1989 Meeting of the Society of Surgical Oncology, San Francisco, CA, May 21-24, 1989
21. Nieroda CA, Agnone C, **Sardi A**, Houchens D, Hinkle G, Bondo S, Martin EW Jr. Comparison of biokinetics of first and second generation monoclonal antibodies. Presented to the 80th Annual Meeting of the American Association for Cancer Research (AACR), May 24-27, 1989
22. **Sardi A.** Radioimmunoguided surgery. Presented at the Tulane University, New Orleans, LA, June 7, 1989
23. **Sardi A.** Recurrent colorectal cancer. Presented at Universidad del Valle, Cali, Colombia, July 14, 1989
24. **Sardi A.** Management of oral cavity cancer. Presented at the 1989 National Symposium of Surgery, San Salvador, El Salvador, September 21-24, 1989
25. **Sardi A.** Management of metastatic tumor to the neck with unknown primary. Presented at the 1989 National Symposium of Surgery, San Salvador, El Salvador, September 21-24, 1989
26. **Sardi A.** Management of carcinoma of the breast. Presented at the 1989 National Symposium of Surgery, San Salvador, El Salvador, September 21-24, 1989
27. **Sardi A.** Management of salivary gland tumors. Presented at the 1989 National Symposium of Surgery, San Salvador, El Salvador, September 21-24, 1989
28. **Sardi A.** The use of radioimmunoguided surgery in resecting retroperitoneal recurrent colorectal cancer. Presented in video form at the 1989 meeting of the American College of Surgeons, Atlanta, GA, October 15-20, 1989
29. **Sardi A.** Metastatic tumor to the neck with unknown primary. Presented at the XI Congreso de Actualización Médica, Cirugía y Especialidades, Guayaquil Ecuador, November 20-25, 1989
30. **Sardi A.** Oral cavity cancer. Presented at the XI Congreso de Actualización Médica, Cirugía y Especialidades, Guayaquil Ecuador, November 20-25, 1989
31. **Sardi A.** Surgical management of recurrent colorectal cancer. Presented at the XI Congreso de Actualización Médica, Cirugía y Especialidades, Guayaquil Ecuador, November 20-25, 1989

32. **Sardi A.** Advances in post-surgical adjuvant therapy for colon cancer: Results of recent NCCTG studies. Presented at the annual Joint Meeting of the Louisiana Chapter of the American College of Surgeons and the Surgical Association of Louisiana, New Orleans, LA, January 20-21, 1990
33. **Sardi A.** Management of in-situ breast cancer. Presented to sessions of the Update in Surgical Oncology - Use of the Cavitron (CUSA) and Intraoperative Ultrasound program, Louisiana State University Medical Center, New Orleans, LA, April 26-27, 1990
34. **Sardi A.** New concepts in the surgical management of metastatic colorectal cancer - radioimmunoguided surgery - isolated hyperthermic liver perfusion. Made presentation as Director of course entitled "Current Management of Gastrointestinal Malignancies," Ochsner Foundation Hospital, New Orleans, LA, May 3-4, 1990
35. **Sardi A.** Surgical management of gastric lymphoma. Made presentation as Director of course entitled "Current Management of Gastrointestinal Malignancies," Ochsner Foundation Hospital, New Orleans, LA, May 3-4, 1990
36. **Sardi A.** Surgical management of recurrent colorectal cancer. Made presentation as Invited Spring Visiting Professor at St. Agnes Hospital in Baltimore, MD, May 16, 1990
37. **Sardi A.** Walters P. DDS. A modified mandibular swing procedure for resection of carcinoma of the oropharynx. (Video). Presented to the Society of Head & Neck Surgeons, Washington DC, May 20-22, 1990
38. Martin EW Jr, Cohen AM, Lavery IC, Daly JM, **Sardi A.**, Aitken D, Bland KI, Hinkle G. Radioimmunoguided surgery: a preliminary report of a multicenter trial to evaluate the use of the radiolabeled B72.3 monoclonal antibody in colorectal cancer. Presented to the Society of Head & Neck Surgeons, Washington DC, May 20-22, 1990
39. **Sardi A.**, Eckholdt G, McKinnon W, Bolton J. The significance of mammography changes following breast preservation for carcinoma of the breast. Poster presentation to the Society of Surgical Oncology, Washington DC, May 20-22, 1990
40. **Sardi A.**, Merritt C, McKinnon W, Mitchell W, Bolton J, DeVun D, Troy D. Stereotactic guidance for breast biopsy localization and aspiration. Presented to the Society of Surgical Oncology, Washington DC, May 20-22, 1990
41. Cohen AM, Martin EW Jr, Lavery I, Daly J, **Sardi A.**, Aitken D, Bland K, Mojzisek C, Hinkle G. Radioimmunoguided surgery using iodine 1251 B72.3 in patients with colorectal cancer. Presented to the 43rd Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, May 21, 1990
42. **Sardi A.**, Facundus E, Eckholdt G, McKinnon W, Bolton J. Management of cancer of the opposite breast following breast preservation. Presented to the 15th International Cancer Congress, Hamburg Germany, August 16-22, 1990
43. **Sardi A.**, Walters P. DDS. A modified mandibular swing procedure for resection of carcinoma of the oropharynx. (Video). Presented to the American College of Surgeons, Clinical Congress, San Francisco, CA, October 7-12, 1990
44. **Sardi A.**, Eckholdt G, McKinnon W, Bolton J. The significance of mammography changes following breast preservation for carcinoma of the breast. Presented to the 84th Annual Scientific Assembly of the Southern Medical Association, Nashville, TN, October 14-17, 1990

45. Lavery I, Aitken D, **Sardi A**, Daly J, Bland K, Cohen A, Martin EW Jr. Phase I/II clinical study: the intraoperative detection of colorectal cancer by radiolabeled B72.3 monoclonal antibody. Presented at the 3rd Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, November 15-17, 1990
46. **Sardi A**. The use of radioimmunoguided surgery in resecting retroperitoneal recurrent colorectal cancer. Presented in video form at the International College of Surgeons, 1991 Annual Meeting, Williamsburg, VA, March 20-24, 1991
47. Sauter E, **Sardi A**. Prognostic Value of DNA Flow Cytometry in Parangliomas of the Head and Neck. Presented to the 84th Annual Scientific Assembly of the Southern Medical Association, Nashville, TN, October 14-17, 1990
48. **Sardi A**. Head and neck cancer. Presented at Tulane University Medical Center, New Orleans, LA, April 1, 1991
49. **Sardi A**. Surgical treatment of recurrent colorectal carcinoma. Presented to the Section of Family Medicine, Ochsner Clinic, New Orleans, LA, April 3, 1991
50. **Sardi A**. Significance of mammography and clinical findings following conservative surgery and radiation. Presented at the Current Concepts in Oncology program at Ochsner Foundation Hospital, New Orleans, LA, April 25-26, 1991
51. **Sardi A**, Bolton J, Mitchell, W, Merritt C. Immunoperoxidase confirmation of ultrasonic-guided fine needle aspirates in patients with recurrent hyperparathyroidism. Presented at the Society of Head and Neck Surgeons, Annual Meeting, Maui, Hawaii, May 1-4, 1991
52. **Sardi A**, Skenderis B. Sisson procedure for resection of carcinoma of the thyroid. Presented at the Society of Head and Neck Surgeons, Annual Meeting, Maui, Hawaii, May 1-4, 1991
53. **Sardi A**. Surgical management of recurrent colorectal carcinoma. Presented at Surgical Grand Rounds at Tulane University Medical Center, New Orleans, LA, May 11, 1991
54. **Sardi A**. Surgical management of recurrent colorectal carcinoma. Presented to the Association of Surgical Technologists 23rd Annual National Conference, New Orleans, LA, June 26-29, 1991
55. **Sardi A**. Program Director for the Spring and Fall meetings of the New Orleans Surgical Society held at Ochsner Foundation Hospital, May 25, 1991, and Tulane University September 20-21, 1991
56. **Sardi A**. Head and Neck Surgery presented at the General Surgery Review Course of the Osler Institute in as mock oral exam preparation with didactic lecture in New Orleans, Louisiana, February 22, 1991; in Pittsburgh, Pennsylvania, September 21, 1991; in Seattle, Washington, June 7, 1991; and in Jacksonville, FL, December 14, 1991
57. **Sardi A**. Management of carcinoma in situ of the breast. Presented at the Fundación Santa Fe de Bogota, Cancer Institute Ardila Lulle, Bogota, Colombia, October 4, 1991
58. **Sardi A**. Surgical management of recurrent cancer of the colon and rectum. Presented at the Fundación Sante Fe de Bogota, Cancer Institute Ardila Lulle, Bogota, Colombia, October 4, 1991
59. **Sardi A**. Immunodirected surgery of metastatic colon carcinoma. Presented at La Academia Nacional de Medicina y Exposalud, Bogota, Colombia, October 5, 1991

60. **Sardi A.** Management of carcinoma in situ of the breast. Presented at the University Hospital, Cali, Colombia, October 7, 1991
61. **Sardi A.** Surgical management of recurrent cancer of the colon and rectum. Presented at the Universidad del Valle, Cali, Colombia, October 7, 1991
62. **Sardi A.** Current management of breast cancer. Presented at the Primary Care of the Hispanic American, Symposium #1, New Orleans, LA, October 24-26, 1991
63. **Sardi A.**, Skenderis B. Sisson procedure for resection of carcinoma of the thyroid. Presented at the American College of Surgeons, 1991 Annual Meeting, Chicago, IL, October 20-25, 1991
64. **Sardi A.** Total pelvic exenteration with or without sacral resection in patients with recurrent rectal carcinoma. Presented at the 85th Scientific Assembly of the Southern Medical Association and the Medical Association of Georgia, Atlanta, GA, November 16-19, 1991
65. **Sardi A.** ¹¹¹In-CYT-103 used in research study. Presented at the Avance en la Detección y Seguimiento del Carcinoma Colorectal, Madrid Spain, December 12, 1991
66. **Sardi A.**, Skenderis B. Sisson procedure for resection of carcinoma of the thyroid. Presented at the International College of Surgeons Annual Meeting, Chicago, IL, April 9-12, 1992
67. **Sardi A.**, Finger IM, Riggs P, Guerra LR, Block MS, Walters PJ. Radiated bone and implants. Presented to the Third International Conference on Head and Neck Cancer, San Francisco, CA, July 1992
68. **Sardi A.** Laparoscopic hernia repair. Presented at the training course. Panama City, Panama, July 23 - 25, 1992
69. **Sardi A.** Laparoscopic hernia repair. Presented at the training course. Fundacion Santa Fe, Bogota, Colombia, July 27, 1992
70. **Sardi A.** Laparoscopic hernia repair. Presented at the training course. Universidad del Valle, Cali, Colombia, July 28, 1992 and August 6, 1992
71. **Sardi A.** The Use of Radioimmunoguided surgery in resection retroperitoneal recurrent colorectal cancer. Presented at 1992 Clinical Congress of the American College of Surgeons, October 11-16, 1992
72. **Sardi A.**, Weiss C. Clinical prognostic factors in patients with metastatic carcinoma with unknown primary. Presented at the 86th Annual Scientific Assembly, Southern Medical Association, San Antonio, TX, November 12-15, 1992
73. **Sardi A.**, Facundus EC, Bergeron R, Bolton JS. Breast Hamartomas: Selective management following mammographic diagnosis. Poster presentation at the 15th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9-10, 1992
74. **Sardi A.**, Skenderis BS, Hoffmann BA, Bolton JS, Willis GW. Ploidy status predicts survival in patients with gastric lymphoma. Presented at the Southeastern Surgical Congress, Tarpon Springs, FL, February 7-11, 1993
75. **Sardi A.** Advances in laparoscopic surgery: Splenectomy, adrenalectomy, hernia. Presented at the 2nd Congress of Private Hospitals of Guatemala, Guatemala City, Guatemala, March 11-13, 1993

76. **Sardi, A.** Witherspoon LR, Bolton JS, Farr GH, Hicks TC, Gathright JB. Monoclonal antibody In-CYT-103 improves detection and management of recurrent colorectal cancer. Presented at The Society of Surgical Oncology meeting, Los Angeles, CA, March 18-21, 1993
77. **Sardi, A.** Laparoscopic splenectomy for a patient with idiopathic thrombocytopenic purpura. Presented at the 46th annual Cancer Symposium of the Society of Surgical Oncology, Los Angeles, CA, March 18-21, 1993
78. **Sardi, A.** Advanced laparoscopic applications. Presented at the Association of Surgical Technologists meeting, New Orleans, LA, March 27, 1993
79. **Sardi, A.** Cirugía laparoscópica su desarrollo y últimos avances. XV Aniversario Fundación, Hospital de Diagnóstico, San Salvador, El Salvador, March 30-April 2, 1993
80. **Sardi, A.** Recurrent colorectal carcinoma. Timing and extent of operation: Do they make a difference? Presented at Advances in the Diagnosis and Management of Colorectal and Ovarian Carcinoma, Puerto Vallarta Mexico, April 22-26, 1993
81. **Sardi, A.** Monoclonal antibodies in the treatment of recurrent colorectal carcinoma. Presented at Oncology Conference of Morton Plant Hospital, Clearwater, FL, May 13, 1993
82. **Sardi, A.** Manejo Actual del Cáncer Gástrico. Presented at XVII Congreso Nacional de Cirugía, Cuenca Ecuador, May 25-26, 1993
83. **Sardi, A.** Laparoscopic splenectomy for a patient with idiopathic thrombocytopenic purpura. Presented at Laparoscopic Procedures Course held at Universidad del Valle, Cali, Colombia; May 28, 1993
84. **Sardi, A.** Laparoscopic splenectomy for a patient with idiopathic thrombocytopenic purpura. Presented at XVII Congreso Nacional de Cirugía, Cuenca Ecuador, May 25-26, 1993
85. **Sardi, A.** Advanced laparoscopic techniques: Colon resection small bowel, resection highly selective vagotomy, adrenalectomy, and splenectomy. Presented at Hospital Universitario del Valle, Cali, Colombia; May 27-28, 1993
86. **Sardi, A.** Estado actual de cirugía laparoscópica. Presented at XVII Congreso Nacional de Cirugía, Cuenca Ecuador, May 25-26, 1993
87. **Sardi, A.** Colectectomía por laparoscopia. Presented at XVII Congreso Nacional de Cirugía, Cuenca, Ecuador, May 25-26, 1993
88. **Sardi, A.** Problemas durante cirugía laparoscópica. Presented at XVII Congreso Nacional de Cirugía, Cuenca Ecuador, May 25-26, 1993
89. **Sardi, A.** Monoclonal antibodies in the management of recurrent colorectal cancer. Presented at Palm Beach Gardens Imaging Center, Palm Beach Gardens, FL, July 30, 1993
90. **Sardi, A.** The surgical management of recurrent colorectal cancer: The role of monoclonal antibodies. Presented at Massapequa General Hospital, Seaport, NY, August 18, 1993
91. **Sardi, A.** The surgical management of recurrent colorectal cancer: The role of monoclonal antibodies. Presented at Long Island College Hospital, Long Island, New York, August 18, 1993
92. **Sardi, A.** McKinnon WMP. Laparoscopic left adrenalectomy for primary aldosteronism. Presented at the 17th Annual Conference at American College of Surgeons, San Francisco, CA, October 10-15, 1993

93. **Sardi, A.** Radical nephrectomy and partial resection of inferior vena cava with extraction of tumor thrombus in renal cell carcinoma. Presented at American College of Surgeons, San Francisco, CA, October 10-15, 1993
94. **Sardi, A.** Laparoscopic splenectomy for a patient with idiopathic thrombocytopenic purpura. Presented at the 4th World Congress International Gastro-Surgical Club in Madrid Spain, October 29, 1993
95. **Sardi, A.** McKinnon WMP. Laparoscopic left adrenalectomy for primary aldosteronism. Presented at the 4th World Congress International Gastro-Surgical Club in Madrid Spain, October 29, 1993
96. **Sardi, A.** Present status of surgical management of recurrent colorectal cancer. Presented at "Theagenion" Cancer Institute in Thessaloniki Greece, November 16, 1993
97. **Sardi, A.** Current status of laparoscopic surgery. Presented at the Aristotelion University of Thessaloniki Medical School, Thessaloniki Greece, November 17, 1993
98. **Sardi, A.** Current status of laparoscopic surgery. Presented at Athens University Medical School, Athens Greece, November 18, 1983
99. **Sardi, A.** Current status of laparoscopic surgery. Presented at the 1st International Aesculapean Seminar on Female Urology, University of Patras Greece, November 20, 1993
100. **Sardi, A.** Surgical aspects of breast cancer. Presented in Cairo Egypt, December 13, 1993
101. **Sardi, A.** The surgical management of recurrent colorectal cancer. Presented in Cairo Egypt, December 13, 1993
102. **Sardi, A.** Laparoscopic assisted small bowel resection. Presented at the International meeting of surgery, Madrid Spain, May 23 1994
103. **Sardi, A.** Surgical management of recurrent colorectal cancer. Presented at XVII International meeting of surgery, Madrid Spain, May 24, 1994
104. **Sardi, A.** Laparoscopic right and left adrenalectomy. Presented at International meeting of surgery, Madrid Spain, May 24, 1994
105. **Sardi, A.** Management of special problems during laparoscopic cholecystectomy. Presented at XVII International meeting of surgery, Madrid Spain, May 26, 1994
106. **Sardi, A.** Gastric cancer; What's new in 1994. Presented at XVII International meeting of surgery, Madrid Spain, May 27, 1994
107. **Sardi, A.** Management of carcinoma in situ of the Breast. Presented at XVII International meeting of surgery, Madrid Spain, May 28, 1994
108. **Sardi, A.** Surgical techniques for tumors. Presented at Symposium on Recent Advances in Cancer Management, Cairo Egypt, June 27, 1994
109. **Sardi, A.** Management of oral cavity cancer. Medical Grand Rounds, Health Care International, Glasgow Scotland, July 6, 1994
110. **Sardi, A.** Management of oral cavity cancer. Surgical Grand Rounds. Saint Agnes Hospital. Baltimore, MD, September 14, 1994

111. **Sardi, A.** Bilateral laparoscopic lumbar sympathectomy. Presented at the 80th Congress of the American College of Surgeons, Chicago, IL, October 11, 1994
112. **Sardi, A.** Cervical lymph node metastasis. Surgical Grand Rounds, North Arundel Hospital, Baltimore, MD, November 17, 1994
113. **Sardi, A.** Cervical lymph node metastasis. Medical Grand Rounds, St. Agnes Hospital, Baltimore, MD, January 26, 1995
114. **Sardi, A.** Manejo del cáncer gástrico. Fundacion Valle del Lili, Primer Simposio de Cancer, Cali, Colombia, February 23, 1995
115. **Sardi, A.** Manejo del cáncer esofágico. Fundacion Valle del Lili, Primer Simposio de Cancer, Cali, Colombia, February 24, 1995
116. **Sardi, A.** Técnicas quirúrgicas en el cáncer primario y metastático del hígado. Fundacion Valle del Lili, Primer Simposio de Cancer, Cali, Colombia, February 23, 1995
117. **Sardi, A.** Surgical management of recurrent colorectal cancer: The role of monoclonal antibodies. Maryland Association of Nuclear Medicine Technology, St. Joseph Hospital, Baltimore, MD, April 26, 1995
118. **Sardi A.** Surgery in Cancer: U.S.-Colombian Medical Association XV Congress New Orleans, LA, July 27- 29, 1995
119. **Sardi A.** Surgical influences in quality of life. St Agnes Hospital Medical Grand Rounds. Baltimore, MD, September 14, 1995
120. **Sardi A.** Liver metastasis. St Agnes Hospital Department of Medicine. Baltimore, MD, November 7, 1995
121. Pergolizzi Jr, J, **Sardi A**, Pelzar M, Merkel Cell carcinoma: An aggressive malignancy. Presented at the 64 Annual Scientific Meeting, Southeastern Surgical Congress, Tampa FL, February 3-7 1996
122. **Sardi A.** Surgical management of recurrent colorectal cancer. Presented at Surgical Grand Rounds. Harbor Hospital Baltimore, MD, February 15, 1996
123. **Sardi A** Management of Sarcomas. Presented at Surgical Grand Rounds. Mercy Hospital Baltimore, MD, February 29, 1996
124. **Sardi A** Surgical management of recurrent colorectal cancer: Role of monoclonal antibodies. Presented at the Maryland Association of Nuclear Medicine Technology. Bethesda, MD, September 28th 1996
125. Cervone, A, **Sardi A.**, Conaway G. Intraoperative ultrasound is essential in the management of metastatic liver lesions. Presented at the 82nd Annual Clinical Congress of the American College of Surgeons, San Francisco, CA, October 6-11, 1996
126. Ehrmantraut, W R, **Sardi A.** Laparoscopic small bowel resection. Presented at the 82nd Annual Clinical Congress of the American College of Surgeons, San Francisco, CA, October 6-11, 1996
127. Pergolizzi Jr, J, **Sardi A** Bolton, J. A prospective randomized study of percutaneous placed versus external jugular venous cut down for long-term venous access. Presented at the 82nd

Annual Clinical Congress of the American College of Surgeons, San Francisco, CA, October 6-11, 1996

128. Stancofski E, **Sardi A**, Conaway G. Successful outcome in Swan-Ganz catheter induced rupture of pulmonary artery. Presented at the SouthEastern Surgical Congress, 65th Annual Scientific Meeting, Nashville, TN, February 3 - 5, 1997
129. Akbarov A, **Sardi A**, Conaway G, Spiegler E, Pelczar M, Roffe M. Radioimmunoguided surgery (RIGS) for patients with intraabdominal metastatic carcinoma of the colon and rectum. Presented at the SouthEastern Surgical Congress, 65th Annual Scientific Meeting, Nashville, TN, February 3 - 5, 1997
130. **Sardi A**, Layne E. Hemicolectomy in a patient with squamous cell carcinoma arising from a sacral decubitus ulcer (Marjolin's ulcer). Video presented at the 83rd Annual Clinical Congress of the American College of Surgeons, Chicago, Illinois 1997
131. **Sardi A**, Sisson procedure for resection of carcinoma of the thyroid. Presented at Greater Baltimore Medical Center. Third Annual Darrell A. Jacques Symposium, Baltimore, MD.
132. Ehrmantraut Jr W, **Sardi A**, Singer JA, Spiegler E. Review of Sestamibi technetium scan for detection of parathyroid adenoma. Presented at the 66th Annual Scientific Meeting of the Southeastern Surgical Congress, Atlanta, GA, February 2-5, 1998
133. Moran J, **Sardi A**, Keramati B. Retrosternal goiter: An unusual radiologic presentation. Presented at the 66th Annual Scientific Meeting of the Southeastern Surgical Congress, Atlanta, GA, February 2-5, 1998
134. Moran JC, **Sardi A**, Singer JA. Retrosternal goiter. Presented at the 66th Annual Scientific Meeting of the Southeastern Surgical Congress, Atlanta, GA, February 2-5, 1998
135. Ojeda H, **Sardi A**. Laparoscopic treatment of a true cyst of the spleen producing high levels of CEA and CA 19-9. Presented at the 66th Annual Scientific Meeting of the Southeastern Surgical Congress, Atlanta, GA, February 2-5, 1998
136. **Sardi A**. Management of primary and metastatic tumors to the liver. Presented at Surgical Grand Rounds, Washington Hospital Center, Washington DC, February 24, 1998
137. **Sardi A**. Minimally invasive procedures in the management of cancer. Internal Medicine Grand Rounds. St. Agnes HealthCare, Baltimore, MD, September 10, 1998
138. Singh K, **Sardi A**, Cotton B. Hemicolectomy for patients with squamous cell carcinoma in chronic pressure ulcers - a review. Presented at 84th Annual Clinical Congress of the American College of Surgeons, Orlando, FL, October 25-30, 1998
139. Stone M, **Sardi A**, Conaway, G. Safe performance of major hepatic resection in a community hospital. Presented at 84th Annual Clinical Congress of the American College of Surgeons, Orlando, FL, October 25-30, 1998
140. Heeringa B, **Sardi A**. Bleeding hepatic adenoma; expectant treatment to limit the extent of liver resection. Presented at 84th Annual Clinical Congress of the American College of Surgeons, Orlando, FL, October 25-30, 1998
141. Ojeda HF, **Sardi A**. Male breast cancer: A 12-year review study of 16 cases with an unusual rate of secondary malignancies. Presented at 84th Annual Clinical Congress of the American College of Surgeons, Orlando, FL, October 25-30, 1998

142. **Sardi A**, Ojeda HF. Laparoscopic treatment of true cyst of the spleen producing high levels of CEA and CA19-9. Video presented in the general surgical section at the 84th annual clinical congress of the American College of Surgeons. Orlando, FL, October 25-30, 1998
143. **Sardi A**. Sentinel node biopsy for breast cancer and melanoma. Presented at the Mid-Eastern Chapter of the Society of Nuclear Medicine. National Institute of Health, Bethesda, MD, November 4, 1998
144. **Sardi A**. Management of sarcoma. Presented at Surgical grand rounds. St. Agnes HealthCare. Baltimore, MD, November 18, 1998
145. **Sardi A**. Minimally invasive procedures in the management of cancer. Presented at OB-Gyn grand rounds. St. Agnes HealthCare. Baltimore, MD, November 18, 1998
146. **Sardi A**. Sentinel lymph node in breast cancer and melanoma. Presented at Centro Medico Imbanaco. Cali, Colombia, December 18, 1998
147. Ojeda HF, **Sardi A**. Cryosurgery: adjuvant treatment at the time of resection of a pelvic recurrence in rectal cancer. Presented at the 67th annual meeting of the Southeastern Surgical Congress. Tampa, FL, February 15, 1999
148. **Sardi A**. Sentinel breast mapping in melanoma and breast cancer. Presented at Frederick Memorial Hospital. Frederick, MD, February 19, 1999
149. **Sardi A**. Sentinel breast mapping in melanoma and breast cancer. Presented at Surgical Grand Rounds St. Joseph Medical Center. Baltimore, MD, March 5, 1999
150. 150. **Sardi A**. Sentinel node mapping in breast cancer and utilization of breast imaging with mammoscintigraphy. Presented in San Diego, CA DuPont Pharmaceuticals Clinical Specialist Groups, March 17, 1999
151. **Sardi A**. Management of breast cancer. Presented in San Diego CA DuPont Pharmaceuticals Clinical Specialist Groups, March 17, 1999
152. **Sardi A**. Sentinel lymph node mapping in breast cancer and melanoma. Presented for Central Pennsylvania Nuclear Medicine Technologist Association. Harrisburg, PA, March 25, 1999
153. **Sardi A**. Sentinel lymph node mapping in breast cancer and melanoma. Presented at Harbor Hospital. Baltimore, MD, April 15, 1999
154. 154. Ojeda H, **Sardi A**, Cotton B, Pelczar M. Adenosquamous cell carcinoma of the breast with recurrent metastases of squamous cell component: An unusual aggressive presentation. Presented at the 85th Congress of American College of Surgeons Clinical Congress, San Francisco, CA, October 11-14, 1999
155. Averbach A, **Sardi A**, Ottaviano Y, Conaway G. Cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in a community teaching hospital. Presented at the 85th Congress of the American College of Surgeons Clinical Congress, San Francisco, CA, October 11-14, 1999
156. McMasters KM, Wong SL, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser, RL, Vennekotter DJ, Turk PS, Tate PS, **Sardi A**, Edwards MJ. Sentinel lymph node (SLN) biopsy for breast cancer. Obtaining a preoperative lymphoscintigram does not improve SLN identification or false-negative rates. Presented at the Southern Surgical Association, Hot Springs, VA, December 5-8, 1999

157. **Sardi A.** The benefit of using two techniques for sentinel lymph node mapping in breast cancer. Presented at 68th annual meeting of the Southeastern Surgical Congress, Lake Buena Vista, FL, February 6-8, 2000
158. **Sardi A.** Kunjummen B, Rehman S, Spiegler E, Colandrea J, Frishberg D, Singh H, Regan P, Totoonchie A, Merchant D. The impact of using two techniques in SLN mapping for breast cancer. Presented at the 10th Congress of the European Society of Surgical Oncology. Groningen Netherlands, April 5-8, 2000
159. **Sardi A.** Aggressive cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy in advanced intraperitoneal malignancies - A pilot study. Presented at the Millenium Master class The Royal College of Surgeons of England. London England, June 1-2, 2000
160. **Sardi A.** Implementation of a protocol for aggressive cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy in peritoneal carcinomatosis and sarcomatosis. Presented at the Milledium Master Class The Royal College of Surgeons of England. London England, June 1-2, 2000
161. **Sardi A.** Advances in the surgical therapy of breast cancer with emphasis on sentinel node biopsy. Presented at the XXth US-Colombian Medical Association Congress, Washington DC, July 8, 2000
162. Averbach A, Kunjummen B, Buscema J, Krishnaiah G, Conaway G, **Sardi A.** Cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of appendiceal, colonic, ovarian and mesothelial origin: Preliminary results of the phase I/II study. Poster Presentation at 69th annual meeting of the Southeastern Surgical Congress, New Orleans, LA, February 3-6, 2001
163. Kunjummen B, **Sardi A.** Safe early postoperative oral feeding after gastrointestinal surgery presented at 69th annual meeting of the Southeastern Surgical Congress, New Orleans, LA, February 3-6, 2001
164. 164 Kunjummen B, **Sardi A.** Previous lumpectomy does not influence the sensitivity of sentinel lymph node mapping in breast cancer. Presented at 69th annual meeting of the Southeastern Surgical Congress, New Orleans, LA, February 3-6, 2001
165. 165 Krishnaiah G, **Sardi A.** Kunjummen B, Regan P, Singer J, Totoonchie A, Spiegler E. Technetium-99M sestamibi scintimammography complements mammography in the detection of breast cancer. Presented at the 6th Annual Multidisciplinary Symposium on Breast Disease, Amelia Island, Florida, February 15-18, 2001
166. 166. Ganti A, **Sardi A.** Gordon J. Laparoscopic treatment of large true cysts of liver and spleen is ineffective. Presented at the 70th Annual meeting of the Southeastern Surgical Congress. Nashville, TN, February 3-5, 2002
167. 167. Averbach A, **Sardi A.** Sher-Ahmad A, Krishnaiah G, Buscema J, Bieligk S. Cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: A pilot study. Presented at The 55th Annual Congress of the Society of Surgical Oncology. Denver, CO, March 14-17, 2002
168. 168. Gann M, **Sardi A.** Improved results using ultrasound guidance for central venous access. Presented at the 71st Annual meeting of the Southeastern Surgical Congress, Savannah, GA, February 7-11, 2003

169. **Sardi A**, Bielick S. Early postoperative oral Intake in a surgical oncology practice. Presented at the 56th Annual Congress of the Surgical Oncology. Los Angeles, CA. March 2003
170. **Sardi A**. Intraductal approach to breast cancer in high-risk patients. Presented at OB/GYN Grand Rounds. St Agnes HealthCare, Baltimore, MD. September 17, 2003
171. **Sardi A**. Minimally invasive approaches in the management of breast cancer. Presented at Medical and Surgical Grand Rounds at Harbor Hospital. Baltimore MD. September 18,2003
172. **Sardi A**. Intraductal approach to breast cancer in high-risk patients. Presented at Medical Grand Rounds St Agnes HealthCare, Baltimore, MD. September 25, 2003
173. **Sardi A**. Aggressive Management of Peritoneal carcinomatosis. Present role of hyperthermic intraoperative intraperitoneal chemotherapy. Presented at The Surgical Grand Rounds North Arundel Hospital. Baltimore, MD. October 16, 2003
174. Green AT, Fleming JB, Ashfaq R, Rege R, **Sardi A**, Bielick S. The utility of laparoscopic peritoneal cytology in patients with malignant disease confined to the abdomen. Presented at the annual congress of the American College of Surgeons, San Francisco, CA 2003
175. **Sardi A**. Sentinel lymph node biopsy in breast cancer. Presented at Centro Imbanaco, Cali, Colombia, December 29, 2003
176. Gann ML. Merriman B **Sardi A**. Safe performance of thyroid and parathyroid surgery in a community teaching hospital. Presented at the annual congress of the SouthEastern Surgical Society, Atlanta, GA. February 1-3, 2004
177. Peterson RM. **Sardi A**. Hemicorporectomy: Seven years of follow up. Presented at the annual congress of the SouthEastern Surgical Society, Atlanta, GA. February 1-3, 2004
178. Hamoudi D. **Sardi A**. Benayache I., Cianos R. Merriman, B. Improved long term survival following Cytoreductive Surgery and Intra-peritoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis. Presented at the Congress of the American College Surgeons Clinical Congress. October 2004
179. Karpinski S., **Sardi A**. Thorascopic Resection of Mediastinal Intrathyroid Parathyroid Adenoma: A case Report. Accepted for presentation to the Southeastern Surgical Congress, New Orleans 11-15, 2005
180. Stephenson S., **Sardi A**. Chest computer tomography for lung screening. Accepted for presentation to the Southeastern Surgical Congress, New Orleans, February 11-15 2005
181. Peterson R., **Sardi A**. Analytic Uncertainty and Clinical Impact of Human Growth Factor Receptor-2 (HER-2/neu) Testing in a Community Hospital. Accepted for presentation to the Southeastern Surgical Congress, New Orleans, February 11-15 2005
182. Hamdalah I, **Sardi A**. Absence of the Retrohepatic Inferior Vena Cava-What the surgeon should know. Accepted for presentation to the Southeastern Surgical Congress, New Orleans, February 11-15 2005
183. Hamdalah I, **Sardi A**. Diagnostic Value of Preoperative FNA in Follicular and Hurthle Cell Neoplasms. Presented at the 58th Annual Cancer Symposium, Society of Surgical Oncology, Atlanta, February 2005

184. **Sardi A.** Management of Peritoneal Carcinomatosis. Presented at Fundacion Valle del Lili, Cali, Colombia. June 7, 2005
185. **Sardi A.** Intraperitoneal Hyperthermic Chemotherapy (IPHC) for the Treatment Abdominal Carcinomatosis: Indications and results. Presented at the Maryland Medical Convention, October 19, 2005
186. **Sardi A.** Intraperitoneal Hyperthermic Chemotherapy (IPHC) for the Treatment Abdominal Carcinomatosis: Indications and results. Presented at Mercy Medical Center, Baltimore, MD January 25, 2006
187. Bashir A, Bieligm S, Cadogan M, **Sardi A.** Scalp Angiosarcoma with Metastasis to the Lung Presenting as a Bleb. Presented to the Southeastern Surgical Congress Annual Scientific Meeting, February 2006
188. Mallalieu J, Marques M, **Sardi A.** Hyperbaric Oxygen Therapy in the Treatment of Radiation Enteritis: A Solution for a Debilitating Condition. Presented to the Southeastern Surgical Congress Annual Scientific Meeting, February 2006
189. Semino-Mora C, **Sardi A.** Liu H, McAvoy T, Dubois A. Pseudomyxoma Peritonei: An infectious disease? Presented at the 59th Annual Cancer Symposium, SSO, San Diego, CA, March 23-26, 2006
190. Franco G, Kostuik P, Nieroda C, Cianos R, Merriman B, **Sardi A.** Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Disseminated Intraabdominal Carcinomatosis. Presented at the 59th Annual Cancer Symposium, SSO, San Diego, CA, March 23-26, 2006
191. **Sardi A.** Surgical and Chemotherapeutic Management of Peritoneal Neoplasia. Presented at Advances in Gynecologic Oncology Symposium, Mercy Medical Center, Baltimore, MD, April 29, 2006
192. **Sardi A.** The management of liver metastasis. Presented at Surgical Grand Rounds, Mercy Medical Center, Baltimore, MD, May 11, 2006
193. Thillainathan V, Nieroda C, Kostuik P, Merriman B, **Sardi A.** Comparison of Open and Closed Techniques of Delivery of Hyperthermic Chemotherapy following Cytoreductive Surgery in patients with Peritoneal Carcinomatosis. Presented at the American Society of Clinical Oncology Annual Meeting, Atlanta, GA, June 3, 2006
194. Baraki Y, **Sardi A.** Long Term Survival Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Disseminated Appendiceal Tumors. Presented at the American Society of Clinical Oncology Annual Meeting, Atlanta, GA, June 3, 2006
195. **Sardi A.** Current Changes in the Management of Peritoneal Carcinomatosis. Presented at the Symposium on Diagnosis and Treatment of Peritoneal Malignancy. Mercy Medical Center, Baltimore, MD, September 16, 2006
196. Munalula J, Thillainathan V, Nieroda C, Kostuik P, Gushchin V, Holter D, Kalesan B, **Sardi A.** Comparison of Open and Closed Technique for Delivery of Hyperthermic Intraperitoneal Chemotherapy following Cytoreductive Surgery for Peritoneal Carcinomatosis. Presented at the Am College of Surgeons, Chicago, IL, October 8-12, 2006
197. **Sardi A.** Current Challenges in the Management of Peritoneal Carcinomatosis. Presented at National Nurses Oncology Education Day. Mercy Medical Center, Baltimore, MD, November 2, 2006

198. **Sardi A.** Tratamiento multidisciplinario de las metastasis hepáticas. Presented at the 16th Congreso Nacional de Cancerología, Bogotá, Colombia, November 9-12, 2006
199. **Sardi A.** Melanoma. Tratamiento quirúrgico. Presented at the 16th Congreso Nacional de Cancerología. Bogotá, Colombia, November 9-12, 2006
200. **Sardi A.** Tratamiento de la carcinomatosis peritoneal. Presented at the 16th Congreso Nacional de Cancerología. Bogotá, Colombia, November 9-12, 2006
201. Kostuik P, Munalula J, Thillaniathan V, Nieroda C, Gushchin V, Holter D, Kalesan B, **Sardi A.** Comparison of Open and Closed Technique for Delivery of Hyperthermic Intraperitoneal Chemotherapy following Cytoreductive Surgery for Peritoneal Carcinomatosis. Presented at the 5th International Workshop on Peritoneal Surface Malignancy, Milan, Italy, December 4-6, 2006
202. **Sardi A.** The Changing Paradigm in Surgical Oncology. Presented at Medical Grand Rounds. Mercy Medical Center, Baltimore, MD, January 31, 2007
203. Munalula J, Nieroda C, Kostuik P, Holter D, Kalesan B, **Sardi A.** Aggressive Cytoreduction Surgery for Peritoneal Carcinomatosis with Low Incidences of Stoma Creation. Presented to the Southeastern Surgical Congress Annual Scientific Meeting, Savannah, GA, February 10-13, 2007
204. Hamdallah I, Ballo M, **Sardi A.** Lower Incidence of Coexistent Carcinoma in Patients with Atypical Ductal Hyperplasia on Stereotactic Breast Biopsy. Presented to the Southeastern Surgical Congress Annual Scientific Meeting, Savannah, GA, February 10-13, 2007
205. Karras RA, **Sardi A.** Intra-Abdominal and Retroperitoneal Catecholamine Producing Paragangliomas. Presented to the Southeastern Surgical Congress Annual Scientific Meeting, Savannah, GA, February 10-13, 2007.
206. Karras RA, **Sardi A.** Concomitant Multi-Organ Cysts, Renal Cell Carcinoma and Pheochromocytoma in Von Hippel-Lindau Disease: A Case Report. Presented to the Southeastern Surgical Congress Annual Scientific Meeting, Savannah, GA, February 10-13, 2007
207. Munalula J, Nieroda C, Kostuik P, Holter D, Kalesan B, Gushchin V, **Sardi A.** Cytoreductive surgery followed with intraperitoneal hyperthermic chemotherapy in elder patients with appendiceal carcinomatosis. Presented to Society of Surgical Oncology 60th Annual Cancer Symposium, Washington, D.C., March 15-18, 2007
208. **Sardi A.** Multi-disciplinary Approach in the Treatment of Recurrent and Stage IV Colorectal Cancer: A Surgical Perspective. Presented at A Symposium on Diagnosis and Treatment of Gastrointestinal Malignancies. Mercy Medical Center, Baltimore, MD September 29, 2007
209. Gushchin V, Ross A, Miller D, Nieroda C, Kalesan B, Studeman K, Kostuik P, **Sardi A.** Complete Cytoreduction Offers Long-term Survival in Patients with Peritoneal Carcinomatosis from Appendiceal Tumors of Unfavorable Histology. Presented to the American College of Surgeons, San Francisco, CA, October 15, 2008.
210. **Sardi A.** Current Approach to Peritoneal Carcinomatosis of Gastrointestinal Origin. Presented at Symposium in the diagnosis and treatment of peritoneal malignancy. Mercy Medical Center, Baltimore MD, November 1, 2008
211. **Sardi A.** Nieroda C, Gushchin V. Approach to the porta hepaticus during cytoreductive

- surgery: Important technical considerations. Presented at the 6th International Workshop on Peritoneal Surface Malignancy, Lyone, France, November 17-19, 2008.
212. Nieroda C, Jonas S, Kostuik P, **Sardi A.** The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer: A Case Study. Presented at the 2009 Southeastern Surgical Congress Annual Scientific Meeting, Atlanta, GA, February 7-9, 2009
 213. **Sardi A.** Cáncer al Colon. Presented at Taller Informativo De Cancer “Preguntele A Los Expertos.” Johns Hopkins Bayview Medical Center, March 19, 2009.
 214. **Sardi A.** Peritoneal carcinomatosis: Not the end of the road? Presented at the 1st Annual GI Symposium, Mercy Medical Center, Baltimore, MD. October 2, 2009
 215. **Sardi A,** Omohwo C, Nieroda C, Holter D, Athas N, Gushchin V. Bowel Complications in Patients with Peritoneal Carcinomatosis of Appendiceal Origen Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.” Presented to Society of Surgical Oncology 63rd Annual Cancer Symposium, St. Louis, MO. March 3-7, 2010
 216. Thieme H, Gushchin V, **Sardi A,** Athas N. Peritoneal Carcinomatosis in the Geriatric Patient: Outcomes with Cytoreductive Surgery and HIPEC. Presented to Society of Surgical Oncology 63rd Annual Cancer Symposium, St. Louis, MO, March 3-7, 2010
 217. **Sardi A.** Treatment for Peritoneal Carcinomatosis. Presented to the PMP Research Foundation Inaugural Practitioner-Patient Symposium. Upland, PA June 19, 2010
 218. **Sardi A.,** Francis J, Marshall M, MacDonald R, Holter D, Gushchin V. Prophylactic IVC filters in patients undergoing Cytoreductive and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Presented at the 7th International Workshop on Peritoneal Surface Malignancies, Uppsala, Sweden, September 2010
 219. **Sardi A,** Omohwo C, Nieroda C, Holter D, Athas N, Gushchin V. Bowel Complications In Patients with Peritoneal Carcinomatosis of Appendiceal Origen Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presented at the 7th International Workshop on Peritoneal Surface Malignancies, Uppsala, Sweden, September 2010
 220. Mitzel A, McBeth M, Appling S, MacDonald R, **Sardi A.** Intraoperative Upper Extremity Repositioning to Prevent Peripheral Neuropathy in Patients Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Nursing Perspective. Presented at the 7th International Workshop on Peritoneal Surface Malignancies, Uppsala, Sweden, September 2010.
 221. Sardi A. Symposium on Diagnosis and Treatment of Peritoneal Malignancy. Timonium, Maryland, September 23, 2010.
 222. El Halabi H, Gushchin V, Macdonald R, Francis J, **Sardi A.** Patients with high-grade appendix cancer and extensive disease do benefit from Cytoreduction and heated intraperitoneal chemotherapy if complete cytoreduction can be achieved. Presented to Society of Surgical Oncology at 64th Annual Cancer Symposium, San Antonio, TX, March 2-5, 2011.
 223. El Halabi H, Gushchin V, Macdonald R, Francis J, Athas N, **Sardi A.** Lymph node metastasis predicts survival in patients with high grade appendix cancer. Presented to Society of Surgical Oncology at 64th Annual Cancer Symposium, San Antonio, TX, March 2-5, 2011.

224. **Sardi A.** Peritoneal carcinomatosis: Not the end of the road. Presented at the Tumor Board at the University of Valle in Cali-Colombia, April 8-2011.
225. El Halabi H, Ledakis P, Gushchin V, Francis J, Athas N, Macdonald R, Studeman K, **Sardi A.** The role of cytoreductive surgery in patients with carcinomatosis from high-grade appendix cancer in the era of modern systemic chemotherapy. Presented to ASCO Annual Meeting in Chicago, IL June 3-5, 2011
226. **Sardi A.** GI Neuroendocrine Tumors: A Team Approach. Presented to 3rd Annual Consensus and Controversies in Gastroenterology & Hepatology. Mercy Medical Center, Baltimore, MD September 23-24, 2011
227. **Sardi A.** Neuroendocrine Tumors: A Team Approach. Presented at Cancer Care: Back to Basics, A Comprehensive Look at A Multidisciplinary Approach in Treatment of Oncological Diseases. The Institute for Cancer Care at Mercy Medical Center, Baltimore, MD February 3, 2012
228. Wosu C, El-Halabi, Wong M, Gallagher B, Francis J, Studeman K, Ledakis P, Nieroda C, Gushchin V, **Sardi A.** Progression of Peritoneal Adenomucinosi s to the Scrotum: A Rare Occurrence Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presented at the Seventh International Symposium on Regional Cancer Therapies, Captiva, Florida, February 18-20, 2012
229. El Halabi H, Gushchin V, Francis J, MacDonald R, Studeman K, Wosu C, Nieroda C, **Sardi A.** Port site metastases in patients with stage IV appendiceal neoplasm. Presented at SSO 65th Annual Symposium, Orlando, Florida, March 2012
230. **Sardi A.** Surgical Options: Management of Primary NETs in the presence of Metastases. Presented to the Neuroendocrine Tumor Regional Conference, Linthicum Heights, MD, April 20, 2012
231. **Sardi A.** Management of Ovarian Cancer with Peritoneal Metastases: This is how we do it. Presented at Workshop on The Management of Peritoneal Metastases; Medstar Washington Hospital Center, Washington, D.C., June 21, 2012
232. **Sardi A.** Manejo de Carcinomatosis Peritoneal. Presented at XII Congreso Sociedad Dominicana De Hematologia Y Oncologia. Dominican Republic, September 6-9, 2012
233. **Sardi A.** Aspectos Tecnicos de la Cirugia Hepatica. Presented at XII Congreso Sociedad Dominicana De Hematologia Y Oncologia. Dominican Republic, September 6-9, 2012
234. **A Sardi,** V Gushchin, C Nieroda, M Sittig, S Shankar, J Francis, R MacDonald. Repeated Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients with Peritoneal Carcinomatosis from Appendiceal Cancer. Presented at the 8th International Workshop on Peritoneal Surface Malignancy, Berlin, Germany, October 30 – November 2, 2012
235. **Sardi A.** The evolution in the surgical management of breast cancer. Presented in Cali, Colombia, November 25, 2012.
236. B Gallagher, **A Sardi,** C Nieroda, H El-Halabi, V Gushchin. Incidental Papillary Carcinoma in Patients Treated Surgically for Benign Thyroid Disease. Poster Presentation at the Southeastern Surgical Congress 2013 Annual Scientific Meeting, Jacksonville, Florida, February 9-12, 2013

237. Shankar S, Sittig M, Nieroda C, MacDonald R, Gushchin V, **Sardi A**. Extended Survival in the Elderly Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at Society of Surgical Oncology 66th Annual Cancer Symposium Meeting in Washington DC, March 6-9, 2013.
238. Shankar S, **Sardi A**, Sittig M, Nieroda C, MacDonald R, Gushchin V. The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Primary Peritoneal Carcinoma (PPC) with Failed Conventional Treatment. Presented at Society of Surgical Oncology 66th Annual Cancer Symposium Meeting in Washington DC, March 6-9, 2013.
239. **Sardi A**, Gushchin V, Nieroda C, Sittig M, Shankar S, Francis J, MacDonald R, Ledakis P. Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at Society of Surgical Oncology 66th Annual Cancer Symposium Meeting in Washington DC, March 6-9, 2013.
240. **Sardi A**. The Role of HIPEC in Rare Gynecological Malignancies. Presented at the 2 Day Medical Education Course with Live HIPEC Surgery at Mercy Medical Center, June 20-21, 2013.
241. **Sardi A**. Peritoneal Carcinomatosis: Not the End of the Road. Presented at the Oncology Grand Rounds at Monter Cancer Center, North Shore LIJ Health System, June 28, 2013.
242. **Sardi A**. Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy in the treatment of peritoneal carcinomatosis. The experience of a specialized center in Baltimore, USA. The Colombian Association of Surgery: National Congress in Surgical Advances in Bogota, Colombia, August 20-23, 2013.
243. Nunez M, **Sardi A**, Nieroda C, Jimenez W, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V. Morbidity of abdominal wall resections (AWR) and reconstructions during cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Presented at the Regional Cancer Therapies Symposium, Feb 15-17 2014
244. Nunez M, **Sardi A**, Nieroda C, Jimenez W, Sittig M, MacDonald R, Gushchin V. Port site metastases is an independent prognostic factor in patients with peritoneal carcinomatosis. Poster Presentation at the SSO conference, March 12-15, 2014
245. Jimenez W, **Sardi A**, Nieroda C, Sittig M, MacDonald R, Nunez M, Milovanov V, Aydin N, Gushchin V. Predictive Factors of Peritoneal Carcinomatosis from Appendiceal Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Poster Presentation at the SSO conference, March 12-15, 2014
246. Aydin N, **Sardi A**, Nieroda C, Jimenez W, Nunez M, Sittig M, MacDonald R, Gushchin V. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: A Peritoneal Surface Malignancy Center Experience. Poster Presentation at the SSO conference, March 12-15, 2014
247. **Sardi A**. The Evolution in The Surgical Management of Breast Cancer. Presented at the nursing school at The Universidad del Valle in Cali, Colombia, April 23, 2014
248. Shigeki K, Brendan M, Sugarbaker P, **Sardi A**, et al. Nomograms to Predict Prognosis in PMP: A Peritoneal Surface Oncology Group International (PSOGI) Multicenter Study – poster presentation May 30-June 3, 2014, Chicago, IL

249. **Sardi, A.** Lessons Learned in CRS & HIPEC in Appendiceal Cancer. Presented at the Third Annual Update and Workshop on Management of Peritoneal Surface Malignancies at the University of Maryland, Baltimore, June 12, 2014.
250. **Sardi, A.** Meet the Experts Video Session. Presented at the Third Annual Update and Workshop on Management of Peritoneal Surface Malignancies at the University of Maryland, Baltimore, June 12, 2014.
251. Milovanov V, **Sardi A**, Sittig M, Gushchin V. Peritoneal Mucinous Carcinomatosis of Appendiceal Origin: AJCC Staging Classification of Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy – presented at the 9th International Congress on Peritoneal Surface Malignancies, The Netherlands, Amsterdam, 9 - 11 October 2014
252. Milovanov V, **Sardi A**, Aydin N, Nieroda C, Sittig M, Nunez MF, Gushchin V. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin– oral presentation 34th Congress of European Society of Surgical Oncology Oct 29-31 2014, Liverpool, UK
253. **Sardi A**, Milovanov V, Nieroda C, Sittig M, Gushchin V. 7th AJCC Staging Classification Correlates with Biological Behavior of Pseudomyxoma Peritonei (PMP) Tumors Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) – Poster presentation at Society of Surgical Oncology Mar 25-28 2014, Houston TX
254. Nunez MF, **Sardi A**, Nieroda C, Milovanov V, Sittig M, Gushchin V. Preoperative Inflammatory and Tumor Markers Associated with Outcomes in Patients with Appendiceal Neoplasms Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy – Poster presentation at Society of Surgical Oncology Mar 25-28 2014, Houston TX
255. Aydin N, Milovanov V, Sittig M, Gushchin V, **Sardi A**. Importance of anastomotic site (AS) resection during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal carcinomatosis (PC) of appendiceal origin – Poster presentation at Society of Surgical Oncology Mar 25-28 2014, Houston TX
256. Nunez MF, **Sardi A**, Gushchin V. Outcomes and Histopathological Correlation According to Age in Patients with Appendiceal Neoplasms after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) – Poster presentation at 2015 Regional Cancer Therapies Cancer symposium Feb 14-16 2015, Clearwater Beach, FL
257. Nunez MF, **Sardi A**, Gushchin V. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Alternative Treatment in Patients with Peritoneal Carcinomatosis from Small Bowel Neuroendocrine Tumors. Poster presentation at 2015 Regional Cancer Therapies Cancer symposium Feb 14-16 2015, Clearwater Beach, FL
258. **Sardi A**. General Physician Participation in the Management of Cancer-oral presentation Colombian Student Congress for Medical Research (CECIM) June 3-6 2015, Santiago de Cali, Valle del Cauca, Colombia
259. **Sardi A**. Myths and Realities in the Surgical Management of Peritoneal Carcinomatosis-oral presentation Colombian Student Congress for Medical Research (CECIM) June 3-6 2015, Santiago de Cali, Valle del Cauca, Colombia

260. **Sardi A.** Repeat HIPEC for Pseudomyxoma Peritonei-oral presentation Peritoneal Dissemination of Cancer: Update of Treatment, Guidelines and Controversies June 11-12 2015, Virginia Beach, Virginia
261. **Sardi A.** Cytoreductive Surgery and HIPEC in the Management of Uterine Sarcoma (US) with Peritoneal Dissemination (PD) Presentation at Regional Cancer Therapies February 13-15 2016, Chandler, Arizona
262. **Sardi A.** A Phase II Randomized Study: Outcomes after Cytoreductive Surgery (CRS) with or without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by Adjuvant Chemotherapy as Initial Treatment. Poster Presentation at Regional Cancer Therapies February 13-15 2016, Chandler, Arizona
263. **Sardi A.** Conference to Raise Awareness About Breast Cancer Care and Prevention. Presented at Embassy of Colombia. April 11, 2016, Washington, DC
264. **Sardi A.** Plan Decenal Para el control de Cáncer en Colombia: Barreras y Posibles Soluciones. Presented at the first Symposium of Cancer de Cuello Uterino. May 5, 2016, Cali, Colombia
265. **Sardi A.** Diaz-Montes TM. Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Presented at the 10th International Congress on Peritoneal Surface Malignancies. November 17-19, 2016. Washington, D.C.
266. **Sardi A.** Radiologic Features to Select Patients for CRS/HIPEC. Presented at the 10th International Congress on Peritoneal Surface Malignancies. November 17-19, 2016. Washington, D.C.
267. Alzahrani NA, Huang Y, Baratti D, et al. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer in 189 Patients (PSOGI Collaboration). Poster presentation at the 10th International Congress on Peritoneal Surface Malignancies. November 17-19, 2016. Washington, D.C.
268. **Sardi A.** Sipok A, Baratti D, Marcelo D, Sugarbaker P, Salti G, Yonemura Y, Sammartino P, Glehen O, Gushchin V, Diaz-Montes T. Multi-Institutional Study of Peritoneal Sarcomatosis from Uterine Sarcoma treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Poster presentation at the 10th International Congress on Peritoneal Surface Malignancies. November 17-19, 2016. Washington, D.C.
269. **Sardi A.** Long-term outcomes with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: An 18-year experience. 2017 ASCO Annual Meeting Abstracts. June 2-6, 2017, Chicago, Illinois
270. **Sardi A.** Sipok A, Nieroda C, Sittig M, Gushchin V. Melphalan versus Mitomycin-C: Similar Survival with More Neutropenia in Patients with Disseminated Colorectal Cancer Treated with Hyperthermic Intraperitoneal Chemotherapy Agent. SSO 71st Annual Cancer Symposium. March 21-24, 2018 Chicago, Illinois.
271. **Sardi A.** Retrospective review of incidental papillary carcinoma in a group of 309 of patients, treated surgically for symptomatic thyroid diseases. 3rd World Congress on Thyroid Cancer. July 27-30, 2017, Boston, Massachusetts
272. **Sardi A.** Articulate Action of Key Stakeholders in the Implementation of Processes for Cancer Control Across the Continuum of Care: A Model Pilot Program. World Cancer Leaders' Summit, "Cities Driving Change." November 13-15, 2017 Mexico City, Mexico.

273. Munoz-Zuluaga CA, **Sardi A.** Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 13th International Symposium on Regional Cancer Therapies. February 17-19, 2018 Jacksonville, FL.
274. Bijelic L, **Sardi A.** Genomic Alterations in Diffuse Malignant Peritoneal Mesothelioma. 13th International Symposium on Regional Cancer Therapies. February 17-19, 2018 Jacksonville, FL.
275. Sipok A, **Sardi A.** Melphalan versus Mitomycin-C: Similar Survival with More Neutropenia in Patients with Disseminated Colorectal Cancer Treated with Hyperthermic Intraperitoneal Chemotherapy Agent. SSO 71st Annual Cancer Symposium. March 21-24, 2018 Chicago, Illinois.
276. Munoz-Zuluaga CA, **Sardi A.** The Role of Preoperative Tumor Markers in Patients with Peritoneal Carcinomatosis from Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. SSO 71st Annual Cancer Symposium. March 21-24, 2018 Chicago, Illinois.
277. Diaz-Montes TP, **Sardi A.** Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer: Preliminary results of a phase II randomized clinical trial. Featured poster presentation at the 49th Annual Meeting of the Society of Gynecologic Oncology. March 24-27, 2018 New Orleans, LA.
278. Diaz-Montes TP, **Sardi A.** Lecturer, Hematology/Oncology Discussion at AAMC, "Use of HIPEC in Ovarian Cancer, The Mercy Experience" May 14, 2018 Anne Arundel Medical Center, Annapolis, MD.
279. Ledakis P, King MC, Munoz C, Gushchin V, Sittig M, **Sardi A.** Preoperative Systemic Chemotherapy in Patients with PMCA of Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presented at the 11th International Workshop on Peritoneal Surface Malignancy, September 9-11, 2018 Paris, France.
280. Munoz-Zuluaga C, King MC, **Sardi A.** Ledakis P, Sittig M, Nieroda C, Gushchin V. Selection and clinical characteristics of exceptional/poor responders in peritoneal dissemination from appendiceal origin treated with CRS/HIPEC. Presented at the 11th International Workshop on Peritoneal Surface Malignancy, September 9-11, 2018 Paris, France.
281. **Sardi A.** Diaz-Montes T, Ryu H, Ducie J, El-Sharkawy F, Sittig M, Gushchin V. Updated Preliminary Results of a Phase II Randomized Clinical Trial – CRS/HIPEC as Initial Treatment for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Presented at the 11th International Workshop on Peritoneal Surface Malignancy, September 9-11, 2018 Paris, France.
282. Diaz-Montes T, Munoz-Zuluaga, Sittig, M, Gushchin V, Nieroda C, **Sardi A.** Outcomes of Stage III and IV Ovarian Cancers after Treatment with Neo-adjuvant Chemotherapy followed by Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Presented at the 11th International Workshop on Peritoneal Surface Malignancy, September 9-11, 2018 Paris, France.
283. Zambrano-Vera K, **Sardi A.** Studeman K, Nieroda C, Sittig M, Munoz-Zuluaga C, Sipok A, Gushchin V. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoid Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at the 14th International Symposium on Regional Cancer Therapies, February 16-19, 2019 Phoenix, Arizona.

284. T.P. Diaz-Montes, C. Velez-Mejia, M. Sittig, R. MacDonald, V. Gushchin, J.A. Ducie, H.S. Ryu and **A. Sardi**. Comparison of perioperative and demographic variables among exceptional and poor responders ovarian cancer patients managed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Presented at the 50th Annual Meeting of the Society of Gynecologic Oncology, March 16-19, 2019 in Honolulu, HI.
285. T.P. Diaz-Montes, C. Velez-Mejia, M. Sittig, R. MacDonald, V. Gushchin, J.A. Ducie, H.S. Ryu and **A. Sardi**. Electrolyte and hematological abnormalities in patients with advanced epithelial ovarian cancers treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or neoadjuvant chemotherapy plus CRS/HIPEC. Presented at the 50th Annual Meeting of the Society of Gynecologic Oncology, March 16-19, 2019 in Honolulu, HI.
286. Zambrano-Vera K, **Sardi A**, Studeman K, Nieroda C, Sittig M, Munoz-Zuluaga C, Sipok A, Gushchin V. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoid Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at the SSO 72nd Annual Cancer Symposium, March 27-30, 2019 in San Diego, California.
287. Velez-Mejia C, **Sardi A**, Spiliotis J, Sittig M, Gushchin V. Genital Necrosis After Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Mitomycin-C. Presented at the SSO 72nd Annual Cancer Symposium, March 27-30, 2019 in San Diego, California.
288. Zambrano-Vera K, **Sardi A**, Munoz-Zuluaga C, Sittig M, Nieroda C, Gushchin V, Diaz-Montes TP. Outcomes in Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at the Advanced Cancer Therapies Annual Meeting, February 15 – 17, 2020 in Orlando, Florida.
289. Baron E, Gushchin V, King MC, Nikiforchin A, **Sardi A**. Pelvic anastomosis without protective ileostomy is safe in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Presented at the Advanced Cancer Therapies Annual Meeting, February 15 – 17, 2020 in Orlando, Florida.
290. Nikiforchin A, King MC, Baron E, MacDonald R, Gushchin V, **Sardi A**. Impact of cellularity in peritoneal metastases on survival in patients with low-grade appendiceal mucinous neoplasm (LAMN). Presented at the Advanced Cancer Therapies Annual Meeting, February 15 – 17, 2020 in Orlando, Florida.
291. Munoz-Zuluaga C, King MC, Diaz-Sarmiento V, Sittig M, Nieroda C, Gushchin V, **Sardi A**. Defining 'Complete Cytoreduction' after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis Incomplete Cytoreduction . Presented at the Advanced Cancer Therapies Annual Meeting, February 15 – 17, 2020 in Orlando, Florida.
292. Munoz-Zuluaga C, Gallo-Perez J, Perez-Bustos A, Orozco-Urdaneta M, Druffel K, Cordoba-Astudillo L, Parra Lara L, Velez C, El-Sharkawy F, Zambrano-Vera K, Hernando Erazo R, King M, **Sardi A**. "Mobile apps: "Breaking barriers to early cancer detection in underserved communities." Video presented at ASCO 2020 Virtual Scientific Program, August 8-10, 2020.
293. J Crystal, J.F. Thompson, A.J. Cochran, et al. Sentinel Lymph Node Biopsy in Melanoma is Therapeutic: Predictors of Long-Term Node Basin Control with SLN Biopsy Alone Presentation at the Society of Surgical Oncology 2020 – International Conference of Surgical Cancer Care, August 17-20, 2020 Virtual Meeting in Boston, Massachusetts.
294. M. Garland-Kledzik, J.F. Thompson, A.J. Cochran et al. The Utility of Ultrasound in the Follow-up of Patients with Melanoma Sentinel Node Metastases Undergoing Observation: An

Analysis of MSLT-II Presentation at the Society of Surgical Oncology 2020 – International Conference of Surgical Cancer Care, August 17-20, 2020 Virtual Meeting in Boston, Massachusetts.

295. Nikiforchin A, King MC, Baron E, MacDonald R, Gushchin V, **Sardi A**. Impact of cellularity in peritoneal metastases on survival in patients with low-grade appendiceal mucinous neoplasm (LAMN). Oral presentation at the Society of Surgical Oncology 2020 – International Conference of Surgical Cancer Care, August 17-20, 2020 Virtual Meeting in Boston, Massachusetts.
296. C.A. Munoz-Zuluaga, M. King, V.S. Diaz-Sarmiento, M. Sittig, C. Nieroda, V. Gushchin, **A. Sardi**. Defining 'Complete Cytoreduction' After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. Presentation at the Society of Surgical Oncology 2020 – International Conference of Surgical Cancer Care, August 17-20, 2020 Virtual Meeting in Boston, Massachusetts.
297. E. Baron, V. Gushchin, M. King, A. Nikiforchin, **A. Sardi**. Pelvic Anastomosis without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presentation at the Society of Surgical Oncology 2020 – International Conference of Surgical Cancer Care, August 17-20, 2020 Virtual Meeting in Boston, Massachusetts.

TRAINING COURSES (Faculty)

1. Head and Neck Surgery review. Presented at the General Surgery Review Course of the Osler Institute as mock oral exam preparation with didactic lecture in New Orleans, Louisiana, February 22, 1991; in Pittsburgh, Pennsylvania, September 21, 1991; in Seattle, Washington, June 7, 1991; and in Jacksonville, Florida, December 14, 1991
2. Laparoscopic hernia repair. Panama City, Panama, July 23-25, 1992.
3. Laparoscopic hernia repair. Fundación Santa Fe, Bogota, Colombia, July 27, 1992.
4. Laparoscopic hernia repair. Universidad del Valle, Cali, Colombia, July 28, 1992; August 6, 1992.
5. Cirugia laparoscopica su desarrollo y ultimos avances. XV Aniversario Fundacion, Hospital de Diagnostico, San Salvador, El Salvador, March 30- April 2, 1993.
6. Advanced laparoscopic techniques: colon resection, small bowel resection, highly selective vagotomy, adrenalectomy and splenectomy. Held at Hospital Universitario del Valle, Cali, Colombia; May 27-28, 1993.
7. Minimally invasive approach to solid organ surgery. Sponsored by The Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland; August 1, 1997. Course Director.
8. Minimally invasive approach to solid organ surgery. Sponsored by The Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. September 29, 1997. Course Director.

9. Minimally invasive approach to solid organ surgery. Sponsored by the Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. February, 1998. Course Director.
10. Minimally invasive approach to solid organ surgery. Sponsored by the Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. June, 1998. Course Director.
11. Minimally invasive approach to solid organ surgery. Sponsored by the Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. September, 1998. Course Director.
12. Minimally Invasive Procedures for Breast Cancer, Melanoma, Hyperparathyroidism. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. Nov. 9-10, 1998. Course Director.
13. Minimally Invasive Procedures for Breast Cancer, Melanoma, Hyperparathyroidism. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. Jan 14-15, 1999. Course Director.
14. Minimally invasive approach to solid organ surgery. Sponsored by the Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. February 26, 1999. Course Director.
15. Minimally invasive approach to solid organ surgery. Sponsored by the Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. April 16, 1999. Course Director.
16. Minimally Invasive Procedures for Breast Cancer, Melanoma, Hyperparathyroidism. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. April 22-23, 1999. Course Director.
17. Minimally invasive approach to solid organ surgery. Sponsored by the Minimally Invasive Surgical Training Institute (MISTI) Held at St. Joseph Medical Center, Baltimore, Maryland. June 14, 1999. Course Director.
18. Minimally Invasive Procedures for Breast Cancer, Melanoma, Hyperparathyroidism. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. September 9-10, 1999. Course Director.
19. Train the Trainer Program for the Mammotome® Hand Held at the Endo-Surgery Institute for the National Launch of the Mammotone® HH. September 29, 1999.
20. Sentinel Node Biopsy for Breast Cancer. Sponsored by the Department of Surgery of Northwest Hospital Center, Baltimore, Maryland. October 2, 1999. Course Faculty.
21. Minimally Invasive Techniques for Breast Care. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. March 10, 2000. Course Director.
22. Minimally Invasive Techniques for Breast Care. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. June 9, 2000. Course Director

23. Minimally Invasive Techniques for Breast Care. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. November 17, 2000. Course Director
24. Minimally Invasive Techniques for Breast Care. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. March 21, 2002. Course Director
25. Minimally Invasive Techniques for Breast Disease. Sponsored by the Clinical Research Center and Comprehensive Breast Center at St. Agnes HealthCare, Baltimore, Maryland. February 6, 2003. Course Director

SPECIAL COURSES:

1. Breast Endoscopy and Intraductal Biopsy Training. Acrueity, Inc., December 2003
2. MammoSite Radiation Therapy System Clinical Training Program. April 2004
3. Seven habits of highly effective management. Franklin Covey, November 2005
4. Fundamentals of Capsule Endoscopy: Clinical Applications and Practice Integration, September 2007
5. Laparoscopic Liver Course, The University of Pittsburgh Liver Cancer Center, September 2006
6. Basic General Surgery, Lower Porcine Program "Da Vinci Training," Philadelphia, PA, May 2011

PUBLICATIONS/MANUSCRIPTS:

1. **Sardi A.** Carcinoma del remanente gástrico: Una entidad clínica insidiosa. *Colombia Medica* 1986;17(4):214-7.
2. **Sardi A,** Singer J. Insulinoma and gastrinoma in Wermer's disease (MEN-1). *Arch Surg.* 1987;122:835-6.
3. **Sardi A,** Gokli A, Singer J. Diverticular disease of the cecum and ascending colon: A review of 881 cases. *Am Surg.* 1987;53:41-5.
4. **Sardi A,** Parikh K, Singer J, Minken S. Mesenteric cysts. *Am Surg.* 1987;53:58-60.
5. **Sardi A,** Minken S. The placement of intracaval filters in an anomalous left-side vena cava. *J Vasc Surg.* 1987;6:84-6.
6. Sickie-Santanello BJ, O'Dwyer PJ, Mojzisek C, Tuttle SE, Hinkle GH, Rousseau M, Schlom J, Thurston MO, Nieroda CA, **Sardi A,** Minton JP, Martin EW Jr. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. *Dis Col Rect.* 1987;30:761-5.
7. **Sardi A,** Minton JP, Nieroda CA, Sickie-Santanello BJ, Young D, Martin EW Jr. Multiple re-operations in recurrent colorectal carcinoma: An analysis of morbidity, mortality and survival. *Cancer* 1988; 61:1913-19.
8. **Sardi A,** Hinkle GH, Hill T, Young D, Siddiqi MA, Agnone CM, Martin EW Jr. Preferential prolonged binding to tumor enhances radioimmunolocalization of monoclonal antibodies. *Internat J Biolog Markers. Pro Amer Assoc Cancer Res* 1988;29:385.

9. Minton JP, Hamilton WB, **Sardi A**, Nieroda CA, Sickle-Santanello BJ, O'Dwyer P. Results of surgical excision of one to thirteen hepatic metastases in 98 consecutive patients. *Arch Surg.* 1989;124:46-8.
10. **Sardi A**, Workman M, Mojzisek C, Hinkle GH, Nieroda CA, Ferrara PJ, Agnone C, Farrar WB, Martin EW Jr. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS™). *Arch Surg.* 1989;124:55-9.
11. Nieroda CA, Mojzisek CM, **Sardi A**, Farrar WB, Siddiqi MA, Ferrara PJ, James A, Thurston MO, Martin EW Jr. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. *Surg Gynecol Obstet.* 1989;169:35-40.
12. **Sardi A**, Minton JP, Mojzisek C, Nieroda CA, Ferrara PJ, Thurston MO, Martin EW Jr. The use of a hand-held gamma detector improves the safety of isolated limb perfusion. *J Surg Oncol.* 1989;41:172-6.
13. Farrar WB, Nieroda CA, Scott M, **Sardi A**. Pancreatic heterotopia: Case report and literature review. *Contemp Surg.* 1989; 35:25-9.
14. Nieroda CA, Siddiqi MA, Hinkle GH, Hill TL, Mojzisek CM, Olsen J, Rousseau M, Gersman M, Houchens D, **Sardi A**, Thurston MO, Martin EW Jr. An assessment of prolonged reactivity of seven monoclonal antibodies against CX-1 tumor xenografts using a novel hand-held gamma detecting probe. *J Invest Surg.* 1989; 2:227-0.
15. **Sardi A**, Siddiqi MA, Hinkle GH, Rousseau M, Gersman M, Hill T, Olsen J, Tuttle S, Young D, Houchens D, Thurston MO, Martin EW Jr. Localization by hand-held gamma detecting probe of tumor labeled with antibody 'cocktail'. *J Surg Res.* 1989;47(3):227-4.
16. **Sardi A**, Agnone C, Nieroda C, Mojzisek C, Hinkle G, Ferrara P, Farrar W, Bolton J, Thurston M, Martin E Jr. Radioimmunoguided surgery in recurrent colorectal cancer: The role of carcinoembryonic antigen, computerized tomography, and physical examination. *So Med J.* October 1989;82:1235-0.
17. Nieroda CA, Mojzisek C, **Sardi A**, Ferrara PJ, Hinkle GH, Thurston MO, Martin EW Jr. The impact of radioimmunoguided surgery (RIGS™) on surgical decision making in colorectal cancer. *Dis Col Rect* November, 1989;32(11):927-2.
18. **Sardi A**, Nieroda CA, Sickle-Santanello BJ, Minton JP, Martin EW Jr. CEA-directed multiple surgical procedures for recurrent colon cancer confined to the liver. *Am Surg* 1990;56(4):255-9.
19. Sauter ER, Bolton JS, Willis GW, Farr G, **Sardi A**. Improved survival after pulmonary resection of metastatic colorectal carcinoma. *J Surg Oncol* 1990;43:135-8.
20. Sauter E, **Sardi A**, Hollier L, Cooper E, Bolton J. Prognostic value of DNA flow cytometry in thymomas and thymic carcinomas. *So Med J* June, 1990;83(6):656-9.
21. Sauter ER, Vauthey JN, **Sardi A**, Bolton JS. Selective management of patients with neutropenic enterocolitis using peritoneal lavage. *J Surg Oncol* 1990;45:63-7.
22. **Sardi A**, Martucci J, Anderson G. In vitro study of implantable devices in the delivery of drugs: A word of caution. *Reg Cancer Treatment*, 1990; 3:228-1.
23. Risher WH, **Sardi A**, Bolton JS. Urachal abnormalities in Adults: The Ochsner Experience. *So Med J* September, 1990; 83(9):1036-9.

24. Nieroda C, Mojzisek C, Ferrara P, **Sardi A**, Hinkle G, Thurston M, Martin EW Jr. Radioimmunoguided surgery in primary colon cancer. *Cancer Detect Prev* 1990;14(6): 651-6.
25. Galloway J, **Sardi A**, DeConti R, Bolton J. Changing trends in thyroid surgery - 38 years' experience. *The American Surgeon*, January 1991; 57(1):18-0.
26. Cohen A, Martin E, Lavery I, Daly J, **Sardi A**, Aitken D, Bland K, Mojzisek C, Hinkle G. Radioimmunoguided surgery: A preliminary report of a multicenter trial to evaluate the use of the radiolabeled B72.3 monoclonal antibody in colorectal cancer. *Arch of Surg*. March 1991; 126(3):349-2.
27. Cohen AM, Martin EW Jr, Lavery I, Daly J, **Sardi A**, Aitken D, Bland K, Mojzisek C, Hinkle G. Radioimmunoguided surgery using iodine B72.3 in patients with colorectal cancer. *Arch Surg* 1991;126:349-2.
28. **Sardi A**, Agnone C, Anderson MS, Bolton J, Sundgaard-Riise K, Nieroda C, Minton J. Low-dose cyclophosphamide enhances helper-to-suppressor ratios. *Cancer Detect Prev* 1991; 15(3):217-4.
29. Sauter E, Hollier L, Bolton J, Ochsner J. **Sardi A**. The prognostic importance of DNA flow cytometry in paragangliomas of the carotid body. *J Surg Onc* 1991;46(3):151-3.
30. **Sardi A**, Facundus E. A simplified aseptic technique to obtain large blood samples in the rat model. *Lab Animal* 1991;20(7):51-2
31. Risher WH, **Sardi A**. Urachal abnormalities in the elderly: A case report. *Surgical Rounds* 1991; 14(7):618-0.
32. **Sardi A**, Walters P. A modified mandibular swing procedure for resection of carcinoma of the oropharynx. *Head & Neck* 1991; September/October, pp 394-7.
33. **Sardi A**, Eckholdt G, McKinnon W, Bolton J. The significance of mammographic findings following breast conserving therapy for carcinoma of the breast. *Surg, Gyn & Obstet* 1991; 173(4):309-2.
34. Nguyen J, McMullen K, **Sardi A**. Lobular carcinoma in situ within a fibroadenoma: A case report. *J La State Med Soc* 1991; 143(10):33-5
35. Bolton JS, **Sardi A**, Merritt, CR, Mitchell WT. Ultrasound guided fine needle aspiration cytology with immunoperoxidase confirmation prior to reexploration for recurrent hyperparathyroidism. *J La State Med Assn* 1991; 143(10):37-1.
36. **Sardi A**, Agnone CM, Pelligrini A. Renal metastases from papillary thyroid carcinoma. *J La State Med Soc* 1992; 144(9): 416-0.
37. **Sardi A**, Facundus E, McKinnon W, Skenderis B, Bolton J. Management of cancer of the opposite breast following breast preservation. *Int Surg* 1992; 77(4): 289-2.
38. Bolton JS, **Sardi A**, Bowen JC, Ellis JK. Transhiatal and transthoracic esophagectomy: A comparative study. *J Surg Onc* 1992; 51(4):249-3.
39. **Sardi A**, Bolton JS, Mitchell WT Jr., Merritt CRB. Immunoperoxidase confirmation of ultrasonic guided fine needle aspirates in patients with recurrent hyperparathyroidism. *Surg Gyn Obstet* 1992; 175(6):563-8.
40. Ferguson ER, **Sardi A**, Beckman EN. Spontaneous rupture of splenic hamartoma: A case report. *J La State Med Soc* 1993; 145(2):48-2.

41. Kuske RR, Farr GH, Harris K, Bolton JS, **Sardi A**, McKinnon WM, Kardinal CG, Cole J, Pickett TK, Graham ML, Fineberg B. Is Breast Preservation Possible in Women with Large, Locally Advanced Breast Cancers? *J La St Med Soc* 1993; 145(4):165-7.
42. **Sardi A**, McKinnon WMP. Laparoscopic Adrenalectomy for Primary Aldosteronism. *JAMA* 1993; 269(8):989-0.
43. **Sardi A**. Colostomy isolation during abdominal surgery. *Intl Surg* 1993; 78(2):146-7.
44. **Sardi A**, McKinnon WM. Laparoscopic Adrenalectomy for Primary Aldosteronism. *Surg Lap & Endos.*, 1994; 4(2): 86-1.
45. **Sardi A**, Bolton JS, Hicks TC, Skenderis BS. Total Pelvic Exenteration With or Without Sacral Resection in Patients with Recurrent Colorectal Cancer. *So Med J*.1994; 87:363-9.
46. **Sardi A**. Laparoscopic Splenectomy for Patients with Thrombocytopenic Purpura. *Surg Lap & Endos* 1994; 4(4): 316-9.
47. Urban J, **Sardi A**, Colandrea J,. Solid and Papillary Epithelial Neoplasm Diagnosis and Treatment: A Case Study. *MMJ* 1995;44:699-2.
48. Metzger N, **Sardi A**, Lawrence G. Laparoscopic adrenalectomy in a patient with Cushing Syndrome. *MMJ* 1996; 45:407-0.
49. Singh K, **Sardi A**, Conaway G, Spiegler E. Gamma detecting probe and isosulphan blue for localization of sentinel node in malignant melanoma. *MMJ* 1996;46:476-1.
50. **Sardi A**, Akbarov A, Conaway G. Management of primary and metastatic tumors to the liver. *Oncology* 1996. 10(6):911-25.
51. Pergolizzi J, **Sardi A**, Pelczar M, Conaway G. Merkle cell carcinoma: An aggressive malignancy. *Am Surg.* 1997; 63:450-4.
52. Irwin JF, **Sardi A**, Waterfield W, Poussin H: Multi modality treatment in the management of esophageal cancer: Neoadjuvant chemo-radiotherapy followed by transhiatal esophagectomy. *MMJ* 1997; 46: 471-6.
53. Ehrmantraut W, **Sardi A**. Laparoscopic assisted small bowel resection. *Am Surg.* 1997; 63:996-001.
54. Eckholdt G, **Sardi A**. The surgical approach to the octogenarian with gastrointestinal malignancy. *Surg Rounds*.1998; 21(6):287-94.
55. Moran J, **Sardi A**, Singer J. Retrosternal Goiter: A six-year institutional review. *Am Surg.* 1998; 64(9):889.
56. McLean R, **Sardi A**. Gastric cancer: An overview with emphasis on early gastric cancer. *MMJ*. August 1998; 47(4):191.
57. Stancofski E, **Sardi A**. Conaway G. Successful outcome in Swan Ganz catheter induced rupture of pulmonary artery. *Am Surg* 1998; 64(11):1062-5
58. **Sardi A**, Ojeda H. Laparoscopic Resection of a Benign True Cyst of the Spleen with the Harmonic Scalpel Producing High Levels of CA 19-9 and Carcinoembryonic Antigen (CEA). *Am Surg.* December, 1998; 64(12):1149-4.

59. Pergolizzi J, Auster M, Conaway G, **Sardi A**. Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature. *Am Surg*. May 1999; 65(5):402-5.
60. Singer J, **Sardi A**, Conaway G, Spiegler E. Minimally invasive parathyroidectomy utilizing a gamma detecting probe intraoperatively. *MMJ*. March/April 1999:55-8.
61. **Sardi A**, Rehman S, Speigler E, Colandrea J, Frishberg D. Sentinel Lymph node mapping for staging breast cancer: Preliminary results of a prospective study. *MMJ*. May/June 1999; 48(3):105-0.
62. **Sardi A**, Ojeda H, Barco, E. Cryosurgery: adjuvant treatment at the time of resection of a pelvic recurrence in rectal cancer. *Am Surg*. November 1999;65(11):1088-1
63. Stone M, **Sardi A**, Conaway, G, Rehman S. Hepatic Resection at a Community Hospital. *J Gastrointestinal Surg*. 2000;4:349-4
64. McMasters K, Wong S, Tuttle T, Carlson D, Brown C, Noyes R, Glaser R, Vennekotter D, Turk P, Tate P, **Sardi A**, Edwards M. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to accurately identify axillary sentinel lymph nodes. *Ann Surg*. 2000 May;231(5):724-1
65. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used. *Journal of Clinical Oncology*. 2000;18(13):2560-2566.
66. Cervone A, **Sardi A**, Conaway G. Intraoperative ultrasound (IOUS) is essential in the management of metastatic liver lesions. *Am Surg*. July 2000;66(7):611-5
67. Ojeda H, **Sardi A**, Totoonchie A. Sarcoidosis of the Breast: Implications for the General Surgeon. *Am Surg*. December 2000;66(12):1144-8
68. Martin R, McMasters K, Edwards M, Wong S, Tuttle T, Carlson D, Tate P, Brown C, Noyes R, Glaser R, Vennekotter D, Turk P, **Sardi A**, Cerrito P. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: Results of a multi-institutional study. *Surgery*. 2000 August;128(2):139-4
69. McMasters K, Tuttle T, Carlson D, Brown C, Noyes R, Glaser R, Vennekotter D, Turk P, Tate P, **Sardi A**, Cerrito P, Edwards M. Sentinel-lymph-node biopsy for breast cancer. A suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. *J Clin Oncol*. 2000 Jul;18(13):2560-6
70. Heeringa B., **Sardi A**. Bleeding hepatic adenoma; expectant treatment to limit the extent of liver resection. *Am Surg*. October 2001;67: 927-9
71. **Sardi A**, Rehman S, Spiegler E, Colandrea J, Frishberg D, Singh H, Regan P, Totoonchie A, Merchant D, Hochuli S, Setya V. The benefit of using two techniques for sentinel lymph node mapping in breast cancer. *Am Surg*. 2002;68(1): 24-8
72. Sher Ahmed A; Buscema J; **Sardi A**. A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy” *Gynecol Oncol*. 2002;86:91-4
73. Averbach A, Akbarov A, Sidel T, Mech K, Parandian B, Waterfield W, Poussin-Ropsillo H, Chang D, **Sardi A**. Results of curative therapy for esophageal cancer in a community training hospital. *Int Surg*. 2002 January-March;87(1):31-7

74. Ganti AI, Gordon J. **Sardi A**. Laparoscopic treatment of large cysts of the liver and spleen is ineffective. *Am Surg*. 2002 Nov;68(11):1012-7
75. Parisky YR, **Sardi A**, Hamm R, Hughes K, Esserman L, Rust S, Callahan K. Efficacy of computerized infrared imaging analysis in the discrimination of mammographically suspicious lesions. *Am J Roentgenol*. 2003 Jan; 180(1): 263-9
76. Krishnaiah G; Sher-Ahmed A; Ugwu-Dike M; Regan P; Singer J; Totoonchie A; Spiegler E; **Sardi A**. Technetium-99M sestamibi scintimamography complements mammography in the detection of breast cancer. *Breast J*. 2003 Jul-Aug;9(4):288-4
77. Del Carmen MG, Hughes KS, Halpern E, Rafferty E, Kopans D, Parisky YR, **Sardi A**, Esserman L, Rust S, Michaelson J. Racial differences in mammographic breast density. *Cancer*. 2003 Aug 1; 98(3):590-6
78. Gann M, **Sardi A**, Bieligm S. Improved results using ultrasound guidance for central venous access. *Am Surg*. 2003; 12:1104-7
79. Peterson RM. **Sardi A**. Hemicorporectomy for chronic pressure ulcer carcinoma: 7 years of follow up. *Am Surg*. 2004 June; 70 (6): 507-1
80. Karpinski S, **Sardi A**. Thorascopic Resection of Mediastinal Intrathymic ParathyroidAdenoma: A case Report. *Am Surg*. 2005 Dec; 71:1070-2
81. Stephenson S, Mech K, **Sardi A**. Lung Cancer Screening with Low-Dose Spiral Computed Tomography. *Am Surg*. 2005 December; 71(12):1015-7
82. Sneed D, Hamdalah I, **Sardi A**. Absence of the Retrohepatic Inferior Vena Cava-What the surgeon should know. *Am Surg*. 2005 June;71(6):502-4
83. Peterson, R, **Sardi A**, Ballo M. Analytic Uncertainty and Clinical Impact of Human Growth Factor Receptor-2 (HER-2/neu) testing in a Community Hospital. *Surgical Rounds* 2006, July; 281-283
84. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan T D, **Sardi A**, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Concensus Statement. *Ann Surg Oncol*. 2007 Jan;14(1):128-33.
85. Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, **Sardi A**, Dubois A. Pseudomyxoma Peritonei: Is disease progression related to microbial agents? A Study of Bacteria, MUC2 and MUC5AC Expression in Disseminated Peritoneal Adenomucinosi and Peritoneal Mucinous Carcinomatosis. *Ann Surg Onc*. 2008 May;15(5):1414-23.
86. Gushchin V, Ross A, Miller D, Nieroda C, Kalesan B, Studeman K, Kostuik P, **Sardi A**. Complete Cytoreduction Offers Long-term Survival in Patients with Peritoneal Carcinomatosis from Appendiceal Tumors of Unfavorable Histology. *JACS* Sept; 2009(3): 308-12.
87. Ross A, **Sardi A**, Nieroda C, Merriman B, Gushchin V. Clinical Utility Of Elevated Tumor Markers In Patients With Disseminated Appendiceal Malignancies Treated by Cytoreductive Surgery And HIPEC. *European Journal of Surgical Oncology* 2010(36): 772-76.
88. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefler R, Morris DL, **Sardi A**, Sticca RP. Accuracy and clinical

relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: A multi-institutional study. *J Surg Oncol.* 2010 Nov 1;102(6): 565-70.

89. El Halabi H, Gushchin V, Francis J, Athas N, MacDonald R, Nieroda C, Studeman K, **Sardi A**. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal cancer and extensive disease. *Ann Surg Oncol* (2012) 19:110-14.
90. El Halabi H, Gushchin V, Francis J, MacDonald R, Athas N, **Sardi A**. Prognostic Significance of Lymph Node Metastases in Patients with High-grade Appendiceal Cancer. *Ann Surg Oncol* (2012) 19:122-25.
91. El Halabi H, **Sardi A**, MacDonald R, Studeman K, Francis J, Nieroda V, Gushchin V. Delay of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients with Appendiceal Neoplasm. *Am Surg* 2012 July;78(7):745-48.
92. Chua T, Moran B, Sugarbaker P, Levine E, Glehen O, Gilly F, Baratti D, Deraco M, ⁷Elias D, ⁸**Sardi A**, ¹Liau W, ³Yan T, ⁹Barrios P, ¹⁰Gómez Portilla A, de Hingh I, Ceelen W, Pelz J, Piso P, González-Moreno S, Van Der Speeten K, Morris D. Early and Long-term Outcome Data on 2298 Patients with Pseudomyxoma Peritonei of Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *J Clin Oncol.* July 2012 30(20):2449-56.
93. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Abdel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominquez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, **Sardi A**, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States. *Ann Surg Oncol.* 2014 May;21(5):1501-5. doi: 10.1245/s10434-013-3061-z
94. Semino-Mora C, Testerman TL, Liu H, Whitmire JM, Studeman K, Jia Y, McAvoy TJ, Francis J, Nieroda C, **Sardi A**, Merrell DS, Dubois A. Antibiotic Treatment Decreases Microbial Burden Associated with Pseudomyxoma Peritonei and Affects β -Catenin Distribution. *Clin Cancer Res.* 2013 Jul 15;19(14):3966-76.
95. Gilbreath J, Semino-Mora C, Friedline C, Liu H, Bodi K, McAvoy T, Francis J, Nieroda C, **Sardi A**, Dubois A, Lazinski D, Camilli A, Testerman T, Merrell D.S. A Core Microbiome Associated with the Peritoneal Tumors of Pseudomyxoma Peritonei. *Orphanet J Rare Dis.* 2013 Jul 12;8(1):105.
96. Jimenez W, **Sardi A**, Ledakis P, Gushchin V, Nieroda C, Falla J, Francis J, MacDonald R, Studeman K. The Role of VEGFR-2 Expression in Outcomes and Survival of Patients with Peritoneal Carcinomatosis from Appendiceal Cancer. *Eur J Surg Oncol.* 2013 Dec;39(12):1415-22. doi: 10.1016/j.ejso.2013.08.032. Epub 2013 Sep 12.
97. **Sardi A**, Jimenez W, Nieroda C, Sittig M, MacDonald R, Gushchin V. Repeated Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis from Appendiceal Cancer: Analysis of Survival Outcomes. *Eur J Surg Oncol.* 2013 Nov;39(11):1207-13. doi: 10.1016/j.ejso.2013.08.017. Epub 2013 Sep 2.
98. **Sardi A**, Jimenez W, Nieroda C, Sittig M, Shankar S, Gushchin V. Melphalan: A promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Onc.* 2014; 21(3):908-914.

99. **Sardi A**, Jimenez WA, Wosu C. Progression of Peritoneal Carcinomatosis to the Scrotum: a Rare Occurrence Treated with Cytoreductive Surgery and Hyperthermic Chemoperfusion of the Scrotum in Two Patients. *Colomb Med.* 2014; 45(2): 77-80.
100. Prada-Villaverde A, Esquivel J, Lowy A, Markman M, Chua T, Pelz J, Baratti D, Baumgartner J, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, **Sardi A**, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies Evaluation of HIPEC with Mitomycin C Versus Oxaliplatin in 539 Patients with Colon Cancer Undergoing a Complete Cytoreductive Surgery. *J Surg Oncol.* 2014 Dec;110(7):779-85. doi: 10.1002/jso.23728. Epub 2014 Aug 2.
101. Jimenez WA, **Sardi A**, Nieroda C, Gushchin V. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal dissemination. *American Journal of Obstetrics and Gynecology* 2014;210(3):259.
102. Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, Morris DL, **Sardi A**, Glehen O, Deraco M and Peritoneal Surface Oncology Group International. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. *Br J Surg.* 2014 Dec;101(13):1758-65. doi: 10.1002/bjs.9674. Epub 2014 Oct 20.
103. Nunez M, **Sardi A**, Jimenez W, Nieroda C, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V. Port-Site Metastases is an Independent Prognostic Factor in Patients with Peritoneal Carcinomatosis. *Ann Surg Oncol.* 2015 Apr;22(4):1267-73. doi: 10.1245/s10434-014-4136-1. Epub 2014 Oct 16.
104. Jimenez W, **Sardi A**, Nieroda C, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V. Predictive and Prognostic Survival Factors in Peritoneal Carcinomatosis from Appendiceal Cancer After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol.* 2014 Dec;21(13):4218-25. doi: 10.1245/s10434-014-3869-1. Epub 2014 Jul 2.
105. Milovanov V, **Sardi A**, Ledakis P, Aydin N, Nieroda C, Sittig M, Nunez M, Gushchin V. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal mucinous carcinomatosis of appendiceal origin. *Eur J Surg Oncol.* 2015 May;41(5):707-12. doi: 10.1016/j.ejso.2015.01.005. Epub 2015 Jan 17.
106. Nunez M, **Sardi A**, Nieroda C, Jimenez W, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V. Morbidity of the Abdominal Wall Resection and Reconstruction After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) *Ann Surg Oncol.* 2015 May;22(5):1658-63 doi: 10.1245/s10434-014-4075-x
107. Milovanov V, **Sardi A**, Aydin N, Nieroda C, Sittig M, Nunez M, Gushchin V. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin. *Eur J Surg Oncol* 2015 Jul;41(7):881-5. doi: 10.1016/j.ejso.2015.02.016.
108. Aydin N, **Sardi A**, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: Experience of a peritoneal surface malignancy center. *Am Surg.* 2015 Dec;81(12):1253-9.
109. Lo AS, Merrell DS, Lei H, **Sardi A**, McAvoy T, Testerman, TL. "A Novel Member of Chitinophagaceae Isolated from a Human Peritoneal Tumor." *Genome Announcements.* *Genome Announc.* 2015 Nov 12;3(6). pii: e01297-15. doi: 10.1128/genomeA.01297-15.

110. Aydin N, **Sardi A**, Milovanov V. Approach to the Porta Hepatis During Cytoreductive Surgery: Technical Considerations. *Ann Surg Oncol*. 2016 Feb;23(2):552-5. doi: 10.1245/s10434-015-4872-x.
111. Milovanov V, **Sardi A**, Studeman K, Nieroda C, Sittig M, Gushchin V. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). *Ann Surg Oncol* 2016;23(6):1928-1933. doi: 10.1245/s10434-015-5047-5.
112. **Sardi A**, Milovanov V, Aydin N, Nieroda C, Sittig M, Gushchin V. External validation of Simplified Pre-operative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. *Ann Surg Oncol*. 2017 Jul; 24(7):1783-1786. doi: 10.1245/s10434-017-5794-6
113. Sugarbaker PH, **Sardi A**, Brown G, Dromain C, Rousset, Jelinek JS. Concerning CT features used to select patients for treatment of peritoneal metastases, a pictorial essay. *Int J Hyperthermia*. 2017 Aug;33(5):497-504. doi: 10.1080/02656736.2017.1317368.
114. **Sardi A**, Sipok A, Díaz-Montes TP, et al. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of primary peritoneal carcinoma. *Journal of Peritoneum (and other serosal surfaces)*. 2017-08-02 2017;2(2).
115. **Sardi A**, Sipok A, Baratti D, et al. Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Eur J Surg Oncol*. Nov 2017;43(11):2170-2177.
116. de Lima A, El-Sharkawy F, Nieroda C, **Sardi A**. Misdiagnosis of a hidden cause of hypertension: a case report. *British Journal of General Practice*. 2017;67(665):578-579.
117. **Sardi A**, Muñoz-Zuluaga CA, Sittig M, Diaz-Montes T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma. *Clinical Case Reports*. 2018;6(6):1142-1152.
118. Diaz-Montes TP, El-Sharkawy F, Lynam S, Harper A, Sittig M, MacDonald R, Gushchin V, **Sardi A**. Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma. *Int J Gynecol Cancer* 2018;28: 1130-1137.
119. Munoz-Zuluaga C, **Sardi A**, King MC, Nieroda C, Sittig M, MacDonald R, Gushchin V. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*. 2018 Dec 6. doi: 10.1245/s10434-018-7007-3. PubMed PMID: 30523470.
120. Sipok A, **Sardi A**, Nieroda C, King MC, Sittig M, Gushchin V. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. *Int J Surg Oncol*. 2018 Dec 13;2018:1920276. doi: 10.1155/2018/1920276. eCollection 2018. PubMed PMID: 30643644; PubMed Central PMCID: PMC6311272.
121. Munoz-Zuluaga C, **Sardi A**, King MC, Nieroda C, Sittig M, MacDonald R, Gushchin V. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*. 2019 Feb;26(2):473-481. doi: 10.1245/s10434-018-7007-3. Epub 2018 Dec 6. PubMed PMID: 30523470.

122. **Sardi A**, Orozco-Urdaneta M, Velez-Mejia C, Perez-Bustos AH, Munoz-Zuluaga C, El-Sharkawy F, Parra-Lara LG, Córdoba P, Gallo D, Sittig M, King MC, Nieroda C, Zambrano-Vera K, Singer J. Overcoming Barriers in the Implementation of Programs for Breast and Cervical Cancers in Cali, Colombia: A Pilot Model. *J Glob Oncol*. 2019 Jul;5:1-9. doi: 10.1200/JGO.19.00054. PubMed PMID: 31260395; PubMed Central PMCID: PMC6613667.
123. Munoz-Zuluaga C, King MC, **Sardi A**, Ledakis P, Sittig M, Nieroda C, MacDonald R, Gushchin V. Selection and Characteristics of Patients with Peritoneal Dissemination from Appendiceal Cancer with Exceptional/Poor Survival After CRS/HIPEC. *Ann Surg Oncol*. 2019 Jul;26(7):2268-2275. doi: 10.1245/s10434-019-07374-z. Epub 2019 Apr 30. PubMed PMID: 31041628.
124. Munoz-Zuluaga CA, King MC, Ledakis P, Gushchin V, Sittig M, Nieroda C, Zambrano-Vera K, **Sardi A**. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. *Eur J Surg Oncol*. 2019 Sep;45(9):1598-1606. doi: 10.1016/j.ejso.2019.05.008. Epub 2019 May 9. PubMed PMID: 31109821.
125. Merrell DS, McAvoy TJ, King MC, Sittig M, Millar EV, Nieroda C, Metcalf JL, Blum FC, Testerman TL, **Sardi A**. Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment. *Eur J Surg Oncol*. 2019 Sep;45(9):1723-1726. doi: 10.1016/j.ejso.2019.01.223. Epub 2019 Jan 30. PubMed PMID: 30770164.
126. Henningsgaard M, Sittig M, Velez-Mejia C, **Sardi A**. Pyoderma Gangrenosum in a Patient with Advanced Rectal Cancer Treated with Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. *Am Surg*. 2019 Nov 1;85(11):e572-e574. PubMed PMID: 31775997.
127. Munoz-Zuluaga C, **Sardi A**. ASO Author Reflections: When the Outliers Become Relevant. *Ann Surg Oncol*. 2019 Dec;26(Suppl 3):690-691. doi: 10.1245/s10434-019-07663-7. Epub 2019 Aug 12. PubMed PMID: 31407177.
128. Zambrano-Vera K, **Sardi A**, Munoz-Zuluaga C, Studeman K, Nieroda C, Sittig M, King MC, Sipok A, Gushchin V. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). *Ann Surg Oncol*. 2020 Jan;27(1):179-187. doi: 10.1245/s10434-019-07932-5. Epub 2019 Oct 23. PubMed PMID: 31646450.
129. Baron E, Milovanov V, Gushchin V, Sittig M, Nieroda C, **Sardi A**. Predicting Aborted Hyperthermic Intraperitoneal Chemotherapy (AHIPEC) with Preoperative Tumor and Inflammatory Markers in Potentially Resectable Appendiceal Cancer Patients with Peritoneal Carcinomatosis. *Ann Surg Oncol*. 2020 Jul;27(7):2548-2556. doi: 10.1245/s10434-019-08117-w. Epub 2020 Jan 24. PubMed PMID: 31980984.
130. Nikiforchin A, King MC, Baron E, MacDonald R, Sittig M, Nieroda C, Gushchin V, **Sardi A**. Impact of Mucin Cellularity and Distribution on Survival in Newly Diagnosed Patients with Low-Grade Appendiceal Mucinous Neoplasm Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*. 2020 May 14;. doi: 10.1245/s10434-020-08535-1. [Epub ahead of print] PubMed PMID: 32409962.
131. Nikiforchin, A., Gushchin, V., King, M.C. et al. ASO Author Reflections: Not All Low-Grade Appendiceal Mucinous Neoplasm Mucin is Created Equal. *Ann Surg Oncol* (2020). doi.org/10.1245/s10434-020-08604-5
132. Baron, E., Gushchin, V., King, M.C. et al. ASO Author Reflections: Is CRS/HIPEC an Indication to Divert Rectal Anastomosis? *Ann Surg Oncol*. 2020 May 20. doi.org/10.1245/s10434-020-08494-7

133. Baron E, Gushchin V, King MC, Nikiforchin A, **Sardi A**. Pelvic Anastomosis Without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*. 2020 Jun 6. doi: 10.1245/s10434-020-08479-6. [Epub ahead of print] PubMed PMID: 32506191.
134. Munoz-Zuluaga C.A., King M.C., Diaz-Sarmiento V.S., Studeman K., Sittig M., MacDonald R., Nieroda C., Zambrano-Vera K. Gushchin V., **Sardi A**. Defining “Complete Cytoreduction” After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. *Ann Surg Oncol*. 2020 Jul 23. doi: 10.1245/s10434-020-08844-5.
135. Lawson PA, Patel NB, Mohammed A, Moore ERB, Lo AS, Sardi A, Davis JM, Doyle DA, Hui Y, Testerman T. Parapseudoflavitalea muciniphila gen. nov., sp. nov., a member of the family Chitinophagaceae isolated from a human peritoneal tumour and reclassification of Pseudobacter ginsenosidimutans as Pseudoflavitalea ginsenosidimutans comb. nov. *Int J Syst Evol Microbiol*. 2020 Jun;70(6):3639-3646. doi: 10.1099/ijsem.0.004204. Epub 2020 Jun 5. PMID: 32501783; PMCID: PMC7395617.
136. King, MC, Munoz-Zuluaga, C, Ledakis, P, et al. Germline and somatic genetic alterations in two first-degree relatives with appendiceal low-grade mucinous carcinoma peritonei. *Clin Case Rep*. 2020; 00: 1– 10. <https://doi.org/10.1002/ccr3.3338>.
137. Lo Dico R, Faron M, Yonemura Y, Glehen O, Pocard M, Sardi A, Hübner M, Baratti D, Liberale G, Kartheuser A, de Hingh I, Sugarbaker P, Ceelen W, Moran B, Robella M, Quenet F, Sideris L, Goere D, Limbert M, Sammartino P, Morris D. Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). *Eur J Surg Oncol*. 2020 Aug 26;. doi: 10.1016/j.ejso.2020.07.038. [Epub ahead of print] PubMed PMID: 32943276.
138. Baron E, Gushchin V, King MC, Nikiforchin A, **Sardi A**. Management of Low-Grade Appendiceal Mucinous Neoplasm with Extensive Peritoneal Spread Diagnosed during Pregnancy: Two Case Reports and Literature Review. *Case Rep Oncol Med*. 2020 Oct 15;2020:8853704. doi: 10.1155/2020/8853704. PMID: 33123396; PMCID: PMC7584972.
139. Munoz-Zuluaga CA, Gallo-Perez JD, Perez-Bustos A, et al. “Mobile apps: Breaking barriers to early cancer detection in underserved communities.” *Journal of Clinical Oncology*. 2020;38(15_suppl):2065-2065. DOI: 10.1200/JCO.2020.38.15_suppl.2065
140. Munoz-Zuluaga CA, **Sardi A**, Sittig M, Gushchin V, King MC, Nieroda C, Lopez-Ramirez F, Diaz-Montes T P, "Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)", *International Journal of Surgical Oncology*, vol. 2020, Article ID 1467403, 14 pages, 2020. <https://doi.org/10.1155/2020/1467403>
141. Kusamura S, Barretta F, Yonemura Y, et al. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. *JAMA Surg*. 2021 Jan 27:e206363. doi: 10.1001/jamasurg.2020.6363. Epub ahead of print. PMID: 33502455; PMCID: PMC7841579.
142. Zambrano-Vera K, **Sardi A**, Lopez-Ramirez F, Sittig M, Munoz-Zuluaga C, Nieroda C, Gushchin V, Diaz-Montes T. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). *Ann Surg Oncol*. 2021 Jan 3. doi: 10.1245/s10434-020-09415-4. Epub ahead of print. PMID: 33393042.

143. Zambrano-Vera K, **Sardi A**, Sittig M, Diaz-Montes T. ASO Author Reflections: The Frailty of Patient Selection. *Annals of Surgical Oncology*. 2021/01/04 2021. Epub ahead of print

PUBLISHED ABSTRACTS

1. Nieroda CA, Farrar WB, Mojzisek C, **Sardi A**, Siddiqi MA, Tuttle JA, Martin EW Jr. Radioimmunoguided surgery: The intraoperative detection of tumor in breast cancer patients. In: Breast cancer research and treatment, William J. McGuire, M.D., ed. - Martinus Nijhoff Publishers. October 1987;10:86
2. **Sardi A**, Hinkle GH, Hill T, Young D, Siddiqi MA, Agnone C, Martin EW Jr. Preferential prolonged binding to tumor enhances radioimmunolocalization of monoclonal antibodies. *Proc Am Assoc Cancer Res* 1988;29:285
3. **Sardi A**, Agnone C, Mojzisek C, Farrar WB, Hinkle GH, Ferrara P, Nieroda CA, Bolton JS, Thurston MO, Martin EW Jr. Radioimmunoguided surgery in recurrent colorectal cancer: The role of CEA, CAT scan and physical examination. *So Med J* 1988;81(9):10
4. **Sardi A**, Agnone C, Anderson G, Bolton J, Sundgaard-Riise K, Nieroda C, Minton J. Low-dose cyclophosphamide enhances helper-to-non-helper ratios. *Cancer Detect Prev* 1989;14(1):121
5. Nieroda C, Mojzisek C, **Sardi A**, Ferrara P, Hinkle G, Thurston M, Martin EW Jr. Radioimmunoguided surgery in primary colon cancer. *Cancer Detect Prev* 1989;14(1):151
6. Nieroda CA, Agnone C, **Sardi A**, Houchens D, Hinkle GH, Bondo S, Martin EW Jr. Comparison of biokinetics of first and second generation monoclonal antibodies. *Am. Assoc. Cancer Res.*, 1989;30(#1428):360
7. Sauter ER, Bolton JS, Willis GW, Farr G, **Sardi A**. Improved survival after pulmonary resection of metastatic colorectal carcinoma. *So Med J* 1989;82:40
8. Risher WH, **Sardi A**, Bolton JS. Urachal abnormalities in adults: The Ochsner experience. *So Med J* 1989;82:97
9. Sauter ER, Hackney JR, Bolton JS, Hollier LH, **Sardi A**. Prognostic value of DNA flow cytometry in thymomas and thymic carcinomas. *So Med J* 1989;82:8
10. **Sardi A**, Eckholdt G, McKinnon W, Bolton J. Management of cancer of the opposite breast following breast preservation. *J Cancer Res Clin Oncol (Part I)* 1990; 116;199. *Intl Surg* 1992;1:262
11. Bolton J, Kuske R, **Sardi A**, McKinnon W, Hawkins R, Scroggins T. Radiation Therapy (RT) in Early Stage Breast Cancer: Can Brachytherapy Replace External Beam Whole Breast Radiation Therapy (WhBRT) in Patients Treated with Breast Conserving Therapy (BCT) - Results of a Pilot Study. *Proc Am Soc Cl Onc*, 148:1993
12. **Sardi A**, Kunjummen B, Rehman S, Spiegler E, Colandrea J, Frishberg D, Singh H, Regan P, Tootonchie A, Merchant D. The impact of using two techniques in SLN mapping for breast cancer. *European Journal of Surgical Oncology* 2000; 26:262
13. **Sardi A** Hamdallah I. Diagnostic Value of Preoperative FNA in Follicular and Hurthle Cell Neoplasms. *Ann Surg Oncol*. 2005;12(2)176:93
14. Semino-Mora C, **Sardi A**, Liu H, McAvoy T, Dubois A. Pseudomyxoma Peritonei: An Infectious disease? *Ann Surg Oncol*. February 2006;13(2)172:83-84.

15. Franco, G., Kostuik, P, Nieroda, C., Cianos, R., Merriman, B. **Sardi A.** Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Disseminated Intra-abdominal Carcinomatosis. *Ann Surg Oncol.* February 2006;13(2)185:87.
16. Baraki Y, Kostuik P, Merriman B, Nieroda C, **Sardi A.** Long term survival following cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for disseminated appendiceal tumors. *J Clin Oncol.* June 2006, 24(18S)4128:209s
17. **Sardi A,** Thillainathan V, Nieroda C, Merriman B, Kostuik P. Comparison of open and closed techniques of delivery of hyperthermic chemotherapy following cytoreductive surgery in patients with peritoneal carcinomatosis. *J Clin Oncol.* June 2006; 24(18S)14067:629s
18. Munalula J, Nieroda C, Kostuik P, Holter D, Kalesan B, Gushchin V, **Sardi A.** Cytoreductive surgery followed with intraperitoneal hyperthermic chemotherapy in elder patients with appendiceal carcinomatosis. *Ann Surg Oncol.* February 2007;14(2)254:109.
19. Gushchin V, Ross A, Nieroda C, Kalesan B, Kostuik P, Holter D, **Sardi A.** Common tumor markers predict extent of disease and success of cytoreductive surgery in patients with appendiceal malignancies. *J Clin Oncol.* May 2008; 26:15527.
20. **Sardi A,** Omohwo C, Nieroda C, Holter D, Athas N, Gushchin V. Bowel Complications In Patients with Peritoneal Carcinomatosis of Appendiceal Origen Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Onco* (2010) 17(Suppl 1) :P165:S85-86.
21. Thieme H, Gushchin V, **Sardi A,** Athas N. Peritoneal Carcinomatosis in the Geriatric Patient: Outcomes with Cytoreductive Surgery and HIPEC. *Ann Surg Oncol.* February 2010;17(1) 290: 123.
22. El Halabi H, Gushchin V, Francis J, MacDonald R, Athas N, **Sardi A.** Lymph node metastasis predicts survival in patients with high-grade appendix cancer. *Ann Surg Oncol.* February 2011; 18(1) 154:86.
23. El Halabi H, Gushchin V, Francis J, MacDonald R, **Sardi A.** Patients with high-grade appendix cancer and extensive disease benefit from cytoreductive surgery and heated intraperitoneal chemotherapy. *Ann Surg Oncol,* February 2011; 18(1) 203:101.
24. El Halabi H, Gushchin V, Francis J, Nieroda C, **Sardi A.** The role of cytoreductive surgery in patients with carcinomatosis from high-grade appendix cancer in the era of modern systemic chemotherapy. *J Clin Oncol* 29: 2011 (suppl; abstr 4080).
25. Chua T, Moran B, Sugarbaker P, Levine E, Glehen O, Gilly F, Baratti D, Deraco M, Elias D, **Sardi A,** Liauw W, Yan T, Barrios P, Gómez Portilla A, de Hingh I, Ceelen W, Pelz J, Piso P, González-Moreno S, Van Der Speeten K, Morris D. Early and Long-term Outcome Data on 2298 Patients with Pseudomyxoma Peritonei of Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *J Clin Oncol* 30, 2012 (suppl 4; abstr 532).
26. **A Sardi,** V Gushchin, C Nieroda, M Sittig, S Shankar, J Francis, R MacDonald, P Ledakis. Intraperitoneal Melphalan in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Poster presentation at the 8th International Workshop on Peritoneal Surface Malignancy, Berlin, Germany, October 30 – November 2, 2012.
27. Shankar S, Sittig M, Nieroda C, MacDonald R, Gushchin V, **Sardi A.** Extended Survival in the Elderly Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy

(CRS/HIPEC). *Proceedings of the Society of Surgical Oncology 66th Annual Cancer Symposium*: P210 (2013).

28. Shankar S, **Sardi A**, Sittig M, Nieroda C, MacDonald R, Gushchin V. The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Primary Peritoneal Carcinoma (PPC) with Failed Conventional Treatment. *Proceedings of the Society of Surgical Oncology 66th Annual Cancer Symposium*: P213 (2013).
29. **Sardi A**, Gushchin V, Nieroda C, Sittig M, Shankar S, Francis J, MacDonald R, Ledakis P. Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). *Proceedings of the Society of Surgical Oncology 66th Annual Cancer Symposium*: P232 (2013).
30. Milovanov V, **Sardi A**, Ledakis P, Aydin N, Jimenez W, Sittig M, Macdonald R, Gushchin V. Systemic chemotherapy (SC) before cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). 2014 ASCO Annual Meeting: e15179
31. Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, **Sardi A**, Senthil M, Spilioitis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. *Ann Surg Oncol*: PMID: 24854493 (2014).
32. Milovanov V, **Sardi A**, Ledakis P, Aydin N, Nieroda C, Sittig M, Nunez M, and Gushchin V. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal mucinous carcinomatosis of appendiceal origin. *Eur J Surg Oncol*, 2015 Jan 7
33. **Sardi A**, Lo AS, Merrell DS, and Testerman TL. "Draft Genome Sequence and Initial Characterization of Novel Bacterial Species Isolated from Pseudomyxoma Peritonei Tumors." Uniformed Services University of the Health Sciences Research Days, Bethesda, MD, 2015.
34. T. Díaz-Montes, M. Rogal, V. Gushchin, C. Nieroda, V. Eskay, **Sardi A**. Ovarian cancer initial experience of hyperthermic intraperitoneal chemotherapy (HIPEC) during interval cytoreduction for the management of advanced stage ovarian/primary peritoneal malignancies. 16th Biennial Meeting of the International Gynecologic Cancer Society Lisbon, Portugal, Volume 26, Supplement 3, October 2016
35. **Sardi A**. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in the treatment of primary peritoneal carcinoma. Presented at the 16th Biennial Meeting of the International Gynecologic Cancer Society, Lisbon, Portugal, Volume 26, Supplement 3, October 2016.
36. Diaz-Montes, T., et al. (2016). "A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by adjuvant chemotherapy as initial treatment of advanced stage (stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer." *Journal of Clinical Oncology* **34**(15_suppl): e17080-e17080.
37. Alzahrani et al. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer in 189 patients. *J of Peritoneum* 2016; 1:s1

38. **Sardi A.** Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J of Peritoneum* 2016; 1:s1
39. Munoz-Zuluaga C, **Sardi A.**, Sittig M, Eskay V, Nieroda C, El-Sharkawy F, Sipok A, Gushchin V. Long-term outcomes with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: An 18-year experience. *J Clin Oncol* 35, 2017 (supple;abstr 4098).
40. **Sardi A.**, Sipok A, Nieroda C, Buitrago F, Studeman K, Sittig M, Eskay V, Gushchin, V. Retrospective Review of Incidental Thyroid Carcinoma in Patients Treated Surgically for Symptomatic Benign Thyroid Disease. EP 66 at World Congress on Thyroid Cancer. July 27-30, 2017; Published online only.
41. C.A. Munoz-Zuluaga,* A. Sardi, R. MacDonald, M. Sittig, C. Nieroda, M. King, V. Gushchin. The Role of Preoperative Tumor Markers in Patients with Peritoneal Carcinomatosis from Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. PF29 at Society of Surgical Oncology 71st Annual Cancer Symposium. Chicago, Illinois March 21-24, 2018; (supple:abstract PF29).
42. **A. Sardi**, A. Sipok, C. Nieroda, M. Sittig, V. Gushchin. Melphalan versus Mitomycin-C: Similar Survival with More Neutropenia in Patients with Disseminated Colorectal Cancer Treated with Hyperthermic Intraperitoneal Chemotherapy Agent. PF59 at Society of Surgical Oncology 71st Annual Cancer Symposium. Chicago, Illinois March 21-24, 2018; (supple:abstract PF59).
43. T.P. Diaz-Montes, F. El-Sharkawy, V. Gushchin, H.S. Ryu, M. Sittig, **A. Sardi**. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer: Preliminary results of a phase II randomized clinical trial. Abstracts Presented for the 49th Annual Meeting of the Society of Gynecologic Oncology. March 24-27, 2018 New Orleans, LA (supple:abstr 68).
44. Ledakis P, King MC, Munoz C, Gushchin V, Sittig M, **Sardi A.** Preoperative Systemic Chemotherapy in Patients with PMCA of Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. In: *Pleura and Peritoneum* 2018; 1, Special Suppl, pp s A6-sA463, September 2018.
45. Munoz-Zuluaga C, King MC, **Sardi A.**, Ledakis P, Sittig M, Nieroda C, Gushchin V. Selection and clinical characteristics of exceptional/poor responders in peritoneal dissemination from appendiceal origin treated with CRS/HIPEC. In: *Pleura and Peritoneum* 2018; 1, Special Suppl, pp s A6-sA463, September 2018.
46. **Sardi A.**, Diaz-Montes T, Ryu H, Ducie J, El-Sharkawy F, Sittig M, Gushchin V. Updated Preliminary Results of a Phase II Randomized Clinical Trial – CRS/HIPEC as Initial Treatment for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. In: *Pleura and Peritoneum* 2018; 1, Special Suppl, pp s A6-sA463, September 2018.
47. Anna Cabanes, Mary Rose Giattas, Mavalynne Orozco-Urdaneta, Groesbeck Parham, Leeya Pinder, Armando Sardi, and Safina Yuma. Different Routes, Similar Destination: Building Breast Care Models in Tanzania, Zambia, and Colombia. In: *Journal of Global Oncology* 4, no. Supplement 3 (October 2018) 7s-7s. DOI: 10.1200/JGO.18.10050
48. Munoz-Zuluaga C, **Sardi A.**, Orozco-Urdaneta M, Parra-Lara LG, Perez A, El-Sharkawy F, et al. A Mobile Application To Improve Access To Early Breast And Cervical Cancer Detection. In: *Journal of Global Oncology* 4, no. Supplement 3 (October 2018) 26s-26s. DOI: 10.1200/JGO.18.10290

49. **Sardi A**, Orozco-Urdaneta M, Velez-Mejia C, Perez A, Munoz-Zuluaga C, El-Sharkawy F, et al. Overcoming Barriers in the Implementation of Programs for Breast and Cervical Cancer: A Pilot Model. In: *Journal of Global Oncology* 4, no. Supplement 3 (October 2018) 39s-39s. DOI: 10.1200/JGO.18.10460
50. Diaz-Montes, T. P., et al. (2019). "Comparison of perioperative and demographic variables among exceptional and poor responders ovarian cancer patients managed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)." *Gynecologic Oncology* 154: 143-144.
51. Diaz-Montes, T. P., et al. (2019). "Electrolyte and hematological abnormalities in patients with advanced epithelial ovarian cancers treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or neoadjuvant chemotherapy plus CRS/HIPEC." *Gynecologic Oncology* 154: 144.
52. Munoz-Zuluaga, C.A., Gallo-Perez, J.D., Perez-Bustos, A., et al. (2020, May 29–31.) Mobile apps: Breaking barriers to early cancer detection in underserved communities [Conference Workshop]. American Society of Clinical Oncology, Chicago, IL, United States.
53. K Zambrano-Vera, **A Sardi**, CA Munoz-Zuluaga, M Sittig, C Nieroda, V Gushchin, T Diaz-Montes Outcomes in Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at the Advanced Cancer Therapies 2020, Orlando Florida February 15-17, 2020.
54. E. Baron, V. Gushchin, M. King, A. Nikiforchin, **A. Sardi**. Pelvic Anastomosis without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presented at the Advanced Cancer Therapies 2020, Orlando Florida February 15-17, 2020.
55. A. Nikiforchin, M. King, E. Baron, R. MacDonald, V. Gushchin, **A. Sardi**. Impact of Cellularity in Peritoneal Metastases on Survival in Patients with Low-Grade Appendiceal Mucinous Neoplasm (LAMN). Presented at the Advanced Cancer Therapies 2020, Orlando Florida February 15-17, 2020.
56. C.A. Munoz-Zuluaga, M. King, V.S. Diaz-Sarmiento, M. Sittig, C. Nieroda, V. Gushchin, **A. Sardi**. Defining 'Complete Cytoreduction' After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. Presented at the Advanced Cancer Therapies 2020, Orlando Florida February 15-17, 2020.
57. Alone C, Thompson JF, Cochran AJ et al. Sentinel Lymph Node Biopsy in Melanoma is Therapeutic: Predictors of Long-Term Node Basin Control with SLN Biopsy. Presented at the Society of Surgical Oncology, SSO 2020 – International Conference on Surgical Cancer Care Boston, Massachusetts March 25 - 28, 2020, Electronic supplement to Annals of Surgical Oncology.
58. A.J. Cochran, J. Hynstrom, C. Caracò. Melanoma Sentinel Node Metastases Undergoing Observation: An Analysis of MSLT-II M. Presented at the Society of Surgical Oncology, SSO 2020 – International Conference on Surgical Cancer Care Boston, Massachusetts March 25 - 28, 2020, Electronic supplement to Annals of Surgical Oncology.
59. A. Nikiforchin, M. King, E. Baron, R. MacDonald, V. Gushchin, **A. Sardi**. Impact of Cellularity in Peritoneal Metastases on Survival in Patients with Low-Grade Appendiceal Mucinous Neoplasm (LAMN). Presented at the Society of Surgical Oncology, SSO 2020 – International Conference on Surgical Cancer Care Boston, Massachusetts March 25 - 28, 2020, Electronic supplement to Annals of Surgical Oncology.

60. C.A. Munoz-Zuluaga, M. King, V.S. Diaz-Sarmiento, M. Sittig, C. Nieroda, V. Gushchin, **A. Sardi**. Defining 'Complete Cytoreduction' After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. Presented at the Society of Surgical Oncology, SSO 2020 – International Conference on Surgical Cancer Care Boston, Massachusetts March 25 - 28, 2020, Electronic supplement to Annals of Surgical Oncology.
61. E. Baron, V. Gushchin, M. King, A. Nikiforchin, **A. Sardi**. Pelvic Anastomosis without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presented at the Society of Surgical Oncology, SSO 2020 – International Conference on Surgical Cancer Care Boston, Massachusetts March 25 - 28, 2020, Electronic supplement to Annals of Surgical Oncology.

BOOK CHAPTERS:

1. Minton JP, **Sardi A**. Carcinomabryonic antigen and second-look operation. Problems in General Surgery; January-March 1987;4(1):104-114.
2. Nieroda CA, **Sardi A**, Martin EW Jr. CEA-directed second-look surgery. In: Current Surgical Therapy-3 Ed: Cameron J. Pg. 155-161. B.C. Decker Inc.: Philadelphia, PA, 1989.
3. **Sardi A**, Minton J, Chevinsky A. Multiple operations for recurrent colorectal cancer. Sem in Surg Oncol, 1991;7:146-156.
4. **Sardi, A.**, Hollier L. Bilateral laparoscopic lumbar sympathectomy. In: Ascer E. Hollier LH, Strandness Jr DE, etal: Haimovici's Vascular Surgery, Principals and Techniques. Fourth edition. Blackwell Science Incorporated 1996. 86;pp 1134-1136.
5. **Sardi, A.** Tratamiento del Carcinoma *In-Situ* de la Mama. pp 533-542 In: Actualización en Cirugía del Aparato Digestivo, Vol. VIII, 2nd edition. Ed: Jarpyo, S.A. 1996.
6. **Sardi, A.** Técnica de Recesión del Intestino Delgado por Laparoscopia Asistida. In: Actualización en Cirugía del Aparato Digestivo, pp 273-276 Vol. VIII, 2nd edition. Ed: Jarpyo, S.A. 1996.
7. **Sardi, A.** Tratamiento del Cáncer Gástrico en 1994. In: Actualización en Cirugía del Aparato Digestivo, pp 321-333 Vol. VIII, 2nd edition. Ed: Jarpyo, S.A. 1996.
8. **Sardi, A.** Problemas Especiales Durante Colicestectomía Laparoscópica. In: Actualización en Cirugía del Aparato Digestivo, pp 201-207 Vol. IX, 2nd edition. Ed: Jarpyo, S.A. 1996.
9. **Sardi, A.** Adrenalectomía por Laparoscopia: Técnica Quirúrgica. In: Actualización en Cirugía del Aparato Digestivo, pp 281-285 Vol. IX, 2nd edition. Ed: Jarpyo, S.A. 1996.
10. **Sardi, A.** Manejo Quirúrgico del Cancer Recurrente del Colon y Recto. pp 353-367 In: Actualización en Cirugía del Aparato Digestivo, Vol. IX, 2nd edition. Ed: Jarpyo, S.A.1996.
11. **Sardi A**, Aggressive Surgical Management of Metastatic Colorectal Cancer to the Liver. Coping November/December 1997, 43-44
12. **Sardi, A.**, Hollier L. Bilateral laparoscopic lumbar sympathectomy. In: Ascer E. Hollier LH, Strandness Jr DE, etal: Haimovici's Vascular Surgery, Principals and Techniques. Fifth edition. Blackwell Science Incorporated 2003. Chapter 55; pp 657-659

13. **Sardi A**, El-Halabi H, Gushchin V, Shankar S. (2012). "Neoplasms of the Appendix: Current Treatment Guidelines." *Hematology/Oncology Clinics of North America* **26**(6): 1261-1290.
14. Munoz-Zuluaga C, Sipok A, **Sardi A**. (2017). Management of Peritoneal Metastasis from Uterine Sarcoma In E Canbay (Ed.), *Unusual Cases in Peritoneal Surface Malignancies* (pp.83-101).

VIDEOS:

1. RADIOIMMUNOGUIDED SURGERY. Martin EW Jr, Nieroda CA, **Sardi A**, Lange M. 41st Annual Meeting of the Southwestern Surgical Congress, April 23-26, 1989, Monterey, California.
2. THE USE OF RADIOIMMUNOGUIDED SURGERY IN RESECTING RETROPERITONEAL RECURRENT COLORECTAL CANCER. **Sardi A**, Martin EW Jr. Presented at the 1989 Annual Meeting of the Society of Surgical Oncology, May 21-24, 1989, San Francisco, CA; Presented at the American College of Surgeons 1989 Clinical Congress, Oct 15-20, 1989 Atlanta, GA; and the American College of Surgeons Medical Motion Picture Library. Presented at the 1992 Clinical Congress Workshop Session of the American College of Surgeons, October 12, 1992. Held in the Motion Picture Library of the American College of Surgery.
3. A MODIFIED MANDIBULAR SWING PROCEDURE FOR RESECTION OF CARCINOMA OF THE OROPHARYNX. **Sardi A**, Walters P. Presented at the 36th Annual Meeting of the Society of Head and Neck Surgeons, May 20-22, 1990, Washington D.C.; Presented at the 1990 Clinical Congress of the American College of Surgeons, October 7-12, San Francisco, CA.
4. ISOLATED HYPERTHERMIC PERFUSION IN THE MANAGEMENT OF METASTATIC COLON CANCER. **Sardi A**, Hayes D.
5. SISSON PROCEDURE FOR RESECTION OF CARCINOMA OF THE THYROID. **Sardi A**, Skenderis B. Presented at the annual meeting of the Society of Head and Neck Surgeons, May 1-4, 1991, Maui, HI; presented at to the 1991 Annual Meeting of the American College of Surgeons, October 20-25, 1991, Chicago, IL. Presented at the 1992 Annual Meeting of the International College of Surgeons. Presented at (Greater Baltimore Medical Center). Held in the motion picture library of the American College of Surgeons. Third Annual Darrell A. Jacques Symposium.
6. THE MANDIBULAR SWING PROCEDURE FOR RESECTION OF CARCINOMA OF THE TONGUE. **Sardi A**, Smith D. 1991.
7. LAPAROSCOPIC HERNIA REPAIR. **Sardi A**. Presented at Panama City, Panama, July 23-25, 1992; also presented at Fundación Santa Fe, Bogota, Colombia, July 27, 1992; also presented at Universidad del Valle, Cali, Colombia, July 28, 1992.
8. LAPAROSCOPIC SPLENECTOMY FOR A PATIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA. **Sardi, A**. Presented at the Society of Surgical Oncology meeting, Los Angeles, CA, March 18-21, 1993. Presented at the Joint Meeting of the Surgical Association of Louisiana and the Louisiana Chapter of the American College of Surgeons, January 23-24, 1993, New Orleans, LA. Presented at the 2nd Congress of Private Hospitals of Guatemala, March 11-13, 1993, Guatemala City, Guatemala. Presented at Laparoscopic Procedures course at Hospital Universitario del Valle, Cali, Colombia, May 28, 1993. Presented at XVII Congreso Nacional de Cirugía; Cuenca, Ecuador, May 25-26, 1993. Presented at the 4th World Congress International and Joint Meeting of Surgery, Gastroenterology and Endoscopy, Madrid, Spain, October 27-30, 1993. Held in the Motion Picture Library of the American College of Surgeons.

9. LAPAROSCOPIC ASSISTED SMALL BOWEL RESECTION. **Sardi A**. Presented at Laparoscopic Procedures course held at Hospital Universitario del Valle, Cali, Colombia; May 25-26, 1993. Presented at XVII International Meeting of Surgery, Madrid, Spain, May 1994.
10. LAPAROSCOPIC POSTERIOR TRUNCAL VAGOTOMY AND ANTERIOR HIGHLY SELECTIVE VAGOTOMY. **Sardi A**. Presented at Laparoscopic Procedures course held at Hospital Universitario del Valle, Cali, Colombia; May 28, 1993. Presented at XVII International Meeting of Surgery, Madrid, Spain, May 1994.
11. LAPAROSCOPIC RIGHT ADRENALECTOMY IN A PATIENT WITH ALDOSTERONOMA. **Sardi A**, McKinnon WMP. Presented at Laparoscopic Procedures course held at Hospital Universitario del Valle, Cali, Colombia; May 28, 1993. Presented at XVII International Meeting of Surgery, Madrid, Spain, May 1994.
12. LAPAROSCOPIC LEFT ADRENALECTOMY FOR PRIMARY ALDOSTERONISM. **Sardi A**, McKinnon WMP. Presented at Laparoscopic Procedures course to be held at Hospital Universitario del Valle, Cali, Colombia; May 28, 1993. Presented at the 1993 Clinical Congress of the American College of Surgeons, San Francisco, CA, October 10-15, 1993. Presented at the 4th World Congress International and Joint Meeting of Surgery, Gastroenterology and Endoscopy, Madrid, Spain, October 27-30, 1993. Presented at XVII International Meeting of Surgery, Madrid, Spain, May 1994. Held in the Motion Picture Library of the American College of Surgeons
13. RADICAL NEPHRECTOMY AND PARTIAL RESECTION OF THE VENA CAVA WITH EXTRACTION OF TUMOR THROMBUS IN RENAL CELL CARCINOMA. **Sardi A**. Presented at the 1993 Clinical Congress of the American College of Surgeons, San Francisco, CA, October 10-15, 1993. Held in the Motion Picture Library of the American College of Surgeons.
14. BILATERAL LAPAROSCOPIC LUMBAR SYMPATHECTOMY. **Sardi A**, Hollier LH. Presented at the Motion Picture exhibition of the American College of Surgeons. Chicago, October 7-12, 1994.
15. HEMICORPECTOMY IN A PATIENT WITH SQUAMOUS CELL CARCINOMA ARISING FROM A SACRAL DECUBITUS ULCER (MARJOLIN'S ULCER). **Sardi A**. Presented at the 83rd Annual Clinical Congress of the American College of Surgeons, Chicago, Illinois, October, 1997. Held in the Motion Picture Library of the American College of Surgeons.
16. LAPAROSCOPIC TREATMENT OF A TRUE CYST OF THE SPLEEN PRODUCING HIGH LEVELS OF CEA AND CA 19-9. **Sardi A**, Ojeda, H. Presented at the American College of Surgeons 1998 Clinical Congress Meeting, Orlando, Florida, October 26, 1998. Held in the Motion Picture Library of the American College of Surgeons.
17. LAPAROSCOPIC RIGHT ADRENALECTOMY FOR PHEOCHROMOCYTOMA **Sardi A**, Submitted for presentation at the Southeastern Surgical Congress, Lake Buena Vista, Florida, February 2000.
18. ULTRASOUND GUIDED PLACEMENT OF CENTRAL VENOUS ACCESS DEVICES. **Sardi A**. Submitted to the Annual Congress of the American College of Surgeons. New Orleans, 2004. Held in the Motion Picture library of the American College of Congress.
19. APPROACH TO THE PORTA HEPATICUS DURING CYTOREDUCTIVE SURGERY: IMPORTANT TECHNICAL CONSIDERATIONS. **Sardi A**, Presented at the 11th International Workshop on Peritoneal Surface Malignancy, Paris, France, September 9-11, 2018.

INVITED COMMENTARIES:

1. **Sardi A**, Aggressive Surgical Management of Metastatic Colorectal Cancer to the Liver. *Coping*. November/December 1997, 43-44.

ANNOUNCEMENTS

1. Lo AS, Merrell DS, Lei H, **Sardi A**, McAvoy T, Testerman TL. 2015. A novel member of *Chitinophagaceae* isolated from a human peritoneal tumor. *Genome Announc* 3(6):e01297-15. doi:10.1128/genomeA.01297-15.

JOURNAL REVIEW:

1. **Sardi A**, Guest Reviewer for *The Annals of Thoracic Surgery*
2. **Sardi A**, Guest Review for *Colombia Médica*

GRANT SUPPORT:

1. Herbert J. Block Memorial Fund - Surgical Oncology Research Fund. **Sardi A**, Minton JP. Toxicity of cyclophosphamide and its effects on the lymphocyte populations in the rat. June 1987-July 1988.
2. MRDF, The Ohio State University. **Sardi A**, Nieroda CA, Minton JP. Highly purified recombinant human Interleukin-2 in the treatment of minimal residual metastatic carcinoma to the liver in the rat. June 1, 1987-May 21, 1988.
3. American Cancer Society, Inc., Ohio Division. **Sardi A**, Minton JP. Evaluation of Interleukin-2 and cyclophosphamide in the treatment of minimal residual disease metastatic to the liver. July 1, 1987-June 30, 1988.
4. MRDF, The Ohio State University. **Sardi A**, Siddiqi MA, Nieroda CA, Martin EW Jr. Determination of ischemic intestine by the Neoprobe™ portable radioisotope detector. August 1, 1987-July 31, 1988.
5. Phase I-II Clinical Study: The intraoperative detection of colorectal cancer by radiolabeled B72.3 monoclonal antibody. Multicenter trial - **Sardi A**, Principal Investigator.
6. Alton Oschner Foundation Medical Research Fund. **Sardi A**. Interleukin-2 and 5-Fluorouracil in the treatment of metastatic adenocarcinoma to the liver in the rat.
7. Alton Oschner Medical Foundation Research Fund. **Sardi A**. Somatostatin analogue SMS 201-995 in the treatment of metastatic colon carcinoma to the liver in the rat.
8. **Sardi A**. A multicenter clinical study using a technetium-labeled monoclonal antibody to evaluate the mediastinum in newly diagnosed non-small cell lung cancer.
9. Alton Oschner Medical Foundation Research Fund. **Sardi A**. HER-2 neu, ras, and myoncogene in human adenocarcinomas.
10. Phase III clinical study: Intraoperative detection of I B72.3 monoclonal antibody in patients with colorectal cancer - multicenter trial - **Sardi A**, Principal Investigator.

11. **Sardi A**, Witherspoon LR, Bolton JS, Timmcke AE, Hicks TC, Ray JE, Gathright GB. ¹¹¹In-CYT-103 as a diagnostic imaging agent in the management of patients with colorectal denocarcinoma. 1990 -1993.
12. Kline R, **Sardi A**, Witherspoon LR. Intravenously administered ¹¹¹In-CYT-103 in the imaging of ovarian cancer. 1990 - 1993.
13. **Sardi A**, Bolton JS, Witherspoon LR, Timmcke AE, Hicks TC. Administration of Repeat Intravenous Doses of ¹¹¹In-CYT-103 in the Detection of Recurrent Colorectal Carcinoma. 1990 - 1993.
14. **Sardi A**, Bolton JS, Witherspoon LR, Timmcke AE, Hicks TC, Ray JE, Hathright GB. Dose-Range Efficacy and Safety of Intravenously Administered ¹¹¹In-CYT-372 in the Imaging of Colorectal Carcinoma. 1990 - 1993.
15. **Sardi A**, Bolton JS, Witherspoon LR, Timmcke AE, Hicks TC, Ray JE, Gathright JB. Intravenously Administered ^{99m}Tc-CYT-380 in the Detection of Colorectal Carcinoma. 1990 - 1993.
16. **Sardi A**, Bardot SF, Witherspoon LR, Bodie BH, Weed WC, Fuselier HA. Administration of Intravenous Doses of ¹¹¹In-CYT-356 in the Detection of Occult Prostrate Carcinoma. 1990 - 1993.
17. **Sardi A**, Bardot SF, Witherspoon LR, Bodie BH, Weed WC, Fuselier HA. Multicenter Study of Intravenously Administered ¹¹¹In-CYT-356 in the Evaluation of Patients with Primary Prostrate Cancer prior to Staging Pelvic Lymph Node Dissection. 1990 - 1993.
18. **Sardi A**, Bolton JS, Hicks TC, Farr GH, Witherspoon LR, Opelka FG, Timmcke AE, Gathright JB, Landry KJ. Comparative Study of the Efficacy and Safety of Intravenously Administered ¹¹¹In-CYT-103 (¹¹¹In-satumomab pentetide) and ¹¹¹In-CYT-372, Given Individually and in Combination, for the Detection of Colorectal Carcinoma. 1990 - 1993.
19. **Sardi A**, Witherspoon LR, Bolton JS, Hicks TC, Timmcke AE, Gathright GB, Landry KJ. Phase II Clinical Study: The Intraoperative Detection of Colon and Rectal Cancer using the CC49 Monoclonal Antibody in Patients with a Prior Exposure to Murine Monoclonal Antibody. 1990 - 1993.
20. **Sardi A**, Hicks TC, Witherspoon LR, Bolton JS, Timmcke AE, Gathright JB, Opelka FG, Farr GH, Landry KJ. Phase III Clinical Study: The comparison of current diagnostic modalities to the radioimmunoguided surgery™ (RIGS®) system using ¹²⁵I CC49 monoclonal antibody for patients with primary adenocarcinoma of the colon and rectum.
21. **Sardi A**, Gralla R, Witherspoon LR, McFadden PM, Bolton JS, Onofrio JM, Shuler SE, Landry KJ. A Multicenter Clinical Study Using a Technetium-Labeled Monoclonal Antibody for Imaging Patient with Small Cell Lung Cancer.
22. **Sardi A**, McFadden PM, Van Meter CH, Witherspoon LR, Bolton JS, Onofrio JM, Gralla R, Emory WB, Shuler SE, Burns CB, Farr GH, Landry KJ. A Multicenter Clinical Study to Compare Imaging of Non-Small Cell Lung Cancer with a Technetium-Labeled Monoclonal Antibody Produced by Two Different Manufacturers.
23. **Sardi A**, Spiegler E, Pelczar M, Roffe M, Merchant D, Totoonchie A, Colandrea J, Zalucki J, Signor W, Setya V, Singer J, Conaway G. A Phase III Clinical Study: The Comparison of Current Diagnostic Modalities to the Radioimmunoguided Surgery (RIGS) System using ¹²⁵I CC49 Monoclonal Antibody for Patients with Intraabdominal Metastatic Adenocarcinoma of the Colon and Rectum. 1994 - 1996.

24. **Sardi A**, Spiegler E, Pelczar M, Roffe M, Merchant D, Totoonchie A, Colandrea J, Zalucki J, Signor W, Setya V, Singer J, Conaway G. Phase III Clinical Study: The Comparison of Current Diagnostic Modalities to the Radioimmunoguided Surgery (RIGS) System using ¹²⁵I CC49 Monoclonal Antibody for Patients with Primary Adenocarcinoma of the Colon and Rectum. 1994 - 1996.
25. **Sardi A**, Spiegler E, Pelczar M, Conaway G. Radioimmunosctintigraphy of Occult Colorectal Carcinoma with OncoSpect (99mTc-88BV59) a Totally Human Monoclonal Antibody Multicenter Study. 1995 - 1997.
26. **Sardi A**, Spiegler E, Pelczar M, Conaway G. Radioimmunosctintigraphy of Recurrent/Metastatic Colorectal Carcinoma with OncoSpect (99mTc-88BV59) a Totally Human Monoclonal Antibody Multicenter Study. 1995 - 1997.
27. **Sardi A**, Spiegler E, Pelczar M, Conaway G. Radioimmunosctintigraphy of Colorectal Carcinoma after Repeat Infusion with OncoSpect (99mTc-88BV59) a Totally Human Monoclonal Antibody Multicenter Study. 1995 - 1997.
28. **Sardi**, Spiegler E, Pelczar M, Conaway G. A Multi-center Evaluation of OncoSPECT CR/Colorectal (^{99m}Tc-88BV59H21-2V67-66) in the Detection of Extrahepatic Metastases in Colorectal Cancer Patients. 1995 - 1997.
29. **Sardi A**, Spiegler E, Pelczar, Roffe M, Conaway G. Phase II Clinical Study: The Intraoperative Detection of Colon and Rectal Cancer Using CC49 Monoclonal Antibody in Patients With a Prior Exposure to Murine Monoclonal Antibody. 1995-1997
30. Buscema J, **Sardi A**, Spiegler E, Conaway G. Radioimmunosctintigraphy with ^{99m}Tc-88BV59 in Patients with Suspected Ovarian Cancer. 1996 - 1997.
31. **Sardi A**, Spiegler E, Gormley P, Mech K, Minken S, Pelczar M, Waterfield W, Conaway G. Phase I/II Study of Radioimmunosctintigraphy with 'X' (Technetium Tc99m Labeled Human Monoclonal Antibody Votumumab) in Patients with Suspected Non-Small Cell Lung Cancer. 1997-1999.
32. **Sardi A**, Spiegler E, Frishberg D, Waterfield W, Ottaviano Y, Gormley P, Griffiths D, Conaway G. Sunbelt Melanoma Trial (SMT): Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients with Early Lymph Node Metastasis Detected by Lymphatic Mapping an. 1997.
33. **Sardi A**, Spiegler E, Conaway G, Brice J. Protocol 9707: Immunoscintigraphy of Colorectal Cancer with Technetium Tc99m Labeled Human Monoclonal Antibody "X" 1998-2000.
34. **Sardi A**, Chen A, Sladek G, Ottaviano Y, Waterfield W, Pelczar M, Conaway G, et al. A Phase I (CAP) with Detox™ PC in adult Patients with Adenocarcinomas of the Gastrointestinal Tract, Breast, Lung. 1997-1998.
35. **Sardi A**, Spiegler E, Totoonchie A, Setya V, Singer J, Signor W, Falcao K, Mercnat D, Parikh K, Meyer G, Hochuli S, Gheba M, Conaway G, Parce P, Regan P. Technetium 99m Sestamibi (Miraluma Tm) Scintimammography in the detection of occult breast cancer 2000-2001.
36. **Sardi A**, Singh R, Singer J, Signor W, Falcao K, Hochuli S, Merchant D, Totoonchie A, Setya V, Hayward G, Parikh K, Meyer G, Gheba M, Regan, P, White R, Hazlinsky N. Clinical study of the Examination of Breasts for the Identification of Suspicious Tissue using Clinical Examination and Mammography with and without computerized Thermal Imaging System (CTI). 1999-2001

37. **Sardi A**, Meyer GM, Regan P. A Study of the IsoMed™ Pump Model 8472 for the Hepatic Arterial Infusion of Chemotherapy. 2000
38. **Sardi A**, Falcao K, Gheba M, Gormley P, Griffiths D, Meyer GM, Sarshar A, Setya V, Singer J, Totoonchie A, Waterfield W, Zalucki J, Regan P, Flack J. A Non-Randomized Multi-Center Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer 2001.
39. **Sardi A**. Susan G. Komen Breast Cancer Foundation grant to increase minority accrual for STAR trial 2001-2002.
40. **Sardi A**. Susan G. Komen Breast Cancer Foundation Grant “Shining Stars: Breaking down barriers to Hispanic and African American Women Participation in Breast Cancer Clinical Trials” May 2002-2003
41. **Sardi A**, Zalucki J, Cain M, Regan P, Conaway G, Parce P. A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL 8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus. 2002
42. **Sardi A**. A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, *CancerVax*® versus BCG plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma. 2002-2005
43. **Sardi A**. A phase III Randomized Double-Blind Trial of Immunotherapy with Vaccine, *CancerVax*® plus BCG versus Placebo plus BCH as a Post-Surgical Treatment for Stage IV Melanoma. 2002-2005.
44. **Sardi, A**. Death P. A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) versus Physician’s Choice Including Interleukin-2 and /or Dacarbazine/Temozolomide Based Therapy and/or Complete Tumor Resection in Stage IV Melanoma.
45. **Sardi, A**. A Prospective Study of The Prognostic Significance of Microsatellite Instability in Patients with Early Age-of-Onset Colorectal Cancer. (Protocol Z0190 – ACOSOG).
46. **Sardi A**. A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec™) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST). 2003-2005.
47. **Sardi A** Identification of Tumor-Associated Surface Proteins, Including Glycoproteins, in Various Cancer Specimens: A Search for Novel Therapeutic Targets. 2003-2006.
48. **Sardi A**. Vishwanathan K. JHH/Ductal Lavage in high-risk patients. 2004-2006.
49. **Sardi A**. Intraductal Approach to breast cancer. Ductoscopy Mammary in patients with nipple discharge. 2004-2006.
50. **Sardi A**. Phase III Randomized Double-blind study of Adjuvant ST1571 (Gleevec™) Versus placebo in patients following the resection of primary gastrointestinal stromal Tumors (GIST). 2005.
51. **Sardi A**. Identification of tumor-associated surface proteins including Glycoproteins in Various cancer specimens: A Search for Novel Therapeutic Targets. 2005.
52. **Sardi A**. Vishwanathan K. JHH/Ductal Lavage in high-risk patients. 2005.

53. **Sardi A.** A Phase II Study of Radiofrequency Ablation of Unresectable Liver Tumors with Hepatic Artery Infusion Chemotherapy. 2006.
54. **Sardi A.** A Prospective Study of The Prognostic Significance of Microsatellite Instability In patients with early age-of-onset Colorectal Cancer (Protocol Z0190-ACOSOG) 2006.
55. **Sardi A.** Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma. 2008-2010.